US6265564B1 - Expressed ligand-vascular intercellular signalling molecule - Google Patents

Expressed ligand-vascular intercellular signalling molecule Download PDF

Info

Publication number
US6265564B1
US6265564B1 US08/740,223 US74022396A US6265564B1 US 6265564 B1 US6265564 B1 US 6265564B1 US 74022396 A US74022396 A US 74022396A US 6265564 B1 US6265564 B1 US 6265564B1
Authority
US
United States
Prior art keywords
leu
tie
gln
glu
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/740,223
Other languages
English (en)
Inventor
Samuel Davis
George D. Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REGENTS PHARMACEUTICALS Inc
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/740,223 priority Critical patent/US6265564B1/en
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to NZ333994A priority patent/NZ333994A/en
Priority to HU0400256A priority patent/HU227995B1/hu
Priority to IL128311A priority patent/IL128311A/en
Priority to CZ1999310A priority patent/CZ295371B6/cs
Priority to KR10-1999-7000894A priority patent/KR100481560B1/ko
Priority to CA002262409A priority patent/CA2262409C/en
Priority to PCT/US1997/013557 priority patent/WO1998005779A1/en
Priority to CA002595037A priority patent/CA2595037A1/en
Priority to JP50808798A priority patent/JP3977434B2/ja
Priority to EP97937086A priority patent/EP0915974B1/en
Priority to ES97937086T priority patent/ES2216163T3/es
Priority to CNB971985316A priority patent/CN1171997C/zh
Priority to RU99105129/13A priority patent/RU2233880C2/ru
Priority to PL97331405A priority patent/PL189639B1/pl
Priority to NZ505684A priority patent/NZ505684A/en
Priority to CA2595038A priority patent/CA2595038C/en
Priority to AU39687/97A priority patent/AU724032C/en
Priority to PT97937086T priority patent/PT915974E/pt
Priority to DK97937086T priority patent/DK0915974T3/da
Priority to AT97937086T priority patent/ATE262037T1/de
Priority to DE69728149T priority patent/DE69728149T2/de
Assigned to REGENERON PHARMACEUTICALS, INC. reassignment REGENERON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAVIS, SAMUEL, YANCOPOULOS, GEORGE D.
Assigned to REGENERON PHARMACEUTICALS, INC. reassignment REGENERON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAVIS, SAMUEL, YANCOPOULOS, GEORGE D.
Priority to NO990470A priority patent/NO990470L/no
Assigned to REGENTS PHARMACEUTICALS, INC. reassignment REGENTS PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAVIS, SAMUEL, YANCOPOULOS, GEORGE D.
Priority to HK99102434A priority patent/HK1017379A1/xx
Priority to US09/709,188 priority patent/US6441137B1/en
Publication of US6265564B1 publication Critical patent/US6265564B1/en
Application granted granted Critical
Priority to NZ514437A priority patent/NZ514437A/xx
Priority to US10/225,060 priority patent/US6825008B2/en
Priority to US10/928,911 priority patent/US20050106099A1/en
Priority to US11/073,120 priority patent/US7045302B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Definitions

  • the present invention relates generally to the field of genetic engineering and more particularly to genes for receptor tyrosine kinases and their cognate ligands, their insertion into recombinant DNA vectors, and the production of the encoded proteins in recipient strains of microorganisms and recipient eukaryotic cells. More specifically, the present invention is directed to a novel modified TIE-2 ligand that binds the TIE-2 receptor, as well as to methods of making and using the modified ligand. The invention further provides a nucleic acid sequence encoding the modified ligand, and methods for the generation of nucleic acid encoding the modified ligand and the gene product.
  • the modified TIE-2 ligand may be useful in the diagnosis and treatment of certain diseases involving endothelial cells and associated TIE receptors, such as neoplastic diseases involving tumor angiogenesis, wound healing, thromboembolic diseases, atherosclerosis and inflammatory diseases.
  • the modified ligand may be used to promote the proliferation and/or differentiation of hematopoietic stem cells.
  • the receptor activating modified TIE-2 ligands described herein may be used to promote the growth, survival, migration, and/or differentiation and/or stabilization or destabilization of cells expressing TIE receptor.
  • Biologically active modified TIE-2 ligand may be used for the in vitro maintenance of TIE receptor expressing cells in culture.
  • Cells and tissues expressing TIE receptor include, for example, cardiac and vascular endothelial cells, lens epithelium and heart epicardium and early hematopoietic cells.
  • human ligand may be used to support cells which are engineered to express TIE receptor.
  • modified TIE-2 ligand and its cognate receptor may be used in assay systems to identify further agonists or antagonists of the receptor.
  • the cellular behavior responsible for the development, maintenance, and repair of differentiated cells and tissues is regulated, in large part, by intercellular signals conveyed via growth factors and similar ligands and their receptors.
  • the receptors are located on the cell surface of responding cells and they bind peptides or polypeptides known as growth factors as well as other hormone-like ligands. The results of this interaction are rapid biochemical changes in the responding cells, as well as a rapid and a long-term readjustment of cellular gene expression.
  • Several receptors associated with various cell surfaces may bind specific growth factors.
  • tyrosine kinases The phosphorylation of tyrosine residues in proteins by tyrosine kinases is one of the key modes by which signals are transduced across the plasma membrane.
  • Several currently known protein tyrosine kinase genes encode transmembrane receptors for polypeptide growth factors and hormones such as epidermal growth factor (EGF), insulin, insulin-like growth factor-I (IGF-I), platelet derived growth factors (PDGF-A and -B), and fibroblast growth factors (FGFs).
  • EGF epidermal growth factor
  • IGF-I insulin-like growth factor-I
  • PDGF-A and -B platelet derived growth factors
  • FGFs fibroblast growth factors
  • growth factors exert their action by binding to the extracellular portion of their cognate receptors, which leads to activation of the intrinsic tyrosine kinase present on the cytoplasmic portion of the receptor.
  • Growth factor receptors of endothelial cells are of particular interest due to the possible involvement of growth factors in several important physiological and pathological processes, such as vasculogenesis, angiogenesis, atherosclerosis, and inflammatory diseases. (Folkman, et al. Science, 235: 442-447 (1987)).
  • the receptors of several hematopoietic growth factors are tyrosine kinases; these include c-fms, which is the colony stimulating factor 1 receptor, Sherr, et al., Cell, 41: 665-676 (1985), and c-kit, a primitive hematopoietic growth factor receptor reported in Huang, et al., Cell, 63: 225-33 (1990).
  • the receptor tyrosine kinases have been divided into evolutionary subfamilies based on the characteristic structure of their ectodomains. (Ullrich, et al. Cell, 61: 243-54 (1990)). Such subfamilies include, EGF receptor-like kinase (subclass 1) and insulin receptor-like kinase (subclass II), each of which contains repeated homologous cysteine-rich sequences in their extracellular domains. A single cysteine-rich region is also found in the extracellular domains of the eph-like kinases. Hirai, et al., Science, 238: 1717-1720 (1987); Lindberg, et al. Mol. Cell.
  • PDGF receptors as well as c-fms and c-kit receptor tyrosine kinases may be grouped into subclass III; while the FGF receptors form subclass IV. Typical for the members of both of these subclasses are extracellular folding units stabilized by intrachain disulfide bonds. These so-called immunoglobulin (Ig)-like folds are found in the proteins of the immunoglobulin superfamily which contains a wide variety of other cell surface receptors having either cell-bound or soluble ligands. Williams, et al., Ann. Rev. Immunol., 6: 381-405 (1988).
  • Receptor tyrosine kinases differ in their specificity and affinity.
  • receptor tyrosine kinases are glycoproteins which consist of (1) an extracellular domain capable of binding the specific growth factor(s); (2) a transmembrane domain which usually is an alpha-helical portion of the protein; (3) a juxtamembrane domain where the receptor may be regulated by, e.g., protein phosphorylation; (4) a tyrosine kinase domain which is the enzymatic component of the receptor; and (5) a carboxyterminal tail which in many receptors is involved in recognition and binding of the substrates for the tyrosine kinase.
  • TIE tyrosine kinase with Ig and EGF homology domains
  • tie mRNA is present in all human fetal and mouse embryonic tissues. Upon inspection, tie message has been localized to the cardiac and vascular endothelial cells. Specifically, tie mRNA has been localized to the endothelia of blood vessels and endocardium of 9.5 to 18.5 day old mouse embryos. Enhanced tie expression was shown during neovascularization associated with developing ovarian follicles and granulation tissue in skin wounds. Korhonen, et al. Blood 80: 2548-2555 (1992). Thus the TIEs have been suggested to play a role in angiogenesis, which is important for developing treatments for solid tumors and several other angiogenesis-dependent diseases such as diabetic retinopathy, psoriasis, atherosclerosis and arthritis.
  • angiogenesis which is important for developing treatments for solid tumors and several other angiogenesis-dependent diseases such as diabetic retinopathy, psoriasis, atherosclerosis and arthritis.
  • tie-1 is the rat homolog of human tie.
  • tie-2 may be the rat homolog of the murine tek gene, which, like tie, has been reported to be expressed in the mouse exclusively in endothelial cells and their presumptive progenitors.
  • the human homolog of tie-2 is described in Ziegler, U.S. Pat. No. 5,447,860 which issued on Sep. 5, 1995 (wherein it is referred to as “ork”), which is incorporated in its entirety herein.
  • tie-2 transcripts were also present in other embryonic cell populations, including lens epithelium, heart epicardium and regions of mesenchyme. Maisonpierre, et al., Oncogene 8: 1631-1637 (1993).
  • TIE vascular endothelia
  • TIE plays a role in the development and maintenance of the vascular system. This could include roles in endothelial cell determination, proliferation, differentiation and cell migration and patterning into vascular elements.
  • Analyses of mouse embryos deficient in TIE-2 illustrate its importance in angiogenesis, particularly for vascular network formation in endothelial cells. Sato, T. N., et al., Nature 376:70-74 (1995). In the mature vascular system, the TIEs could function in endothelial cell survival, maintenance and response to pathogenic influences.
  • the TIE receptors are also expressed in primitive hematopoietic stem cells, B cells and a subset of megakaryocytic cells, thus suggesting the role of ligands which bind these receptors in early hematopoiesis, in the differentiation and/or proliferation of B cells, and in the megakaryocytic differentiation pathway.
  • B cells hematopoietic stem cells
  • megakaryocytic cells hematopoietic stem cells
  • modified TIE-2 ligand refers to a ligand of the TIE family of ligands, whose representatives comprise ligands TL1, TL2, TL3 and TL4 as described herein, which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor.
  • Modified TIE-2 ligand also includes a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first.
  • the first TIE-2 ligand is TL1
  • the second TIE-2 ligand is TL2.
  • the invention envisions other combinations using additional TIE-2 ligand family members.
  • the first ligand is selected from the group consisting of TL1, TL2, TL3 and TL4, and the second ligand, different from the first ligand, is selected from the group consisting of TL1, TL2, TL3 and TL4.
  • the invention also provides for an isolated nucleic acid molecule encoding a modified TIE-2 ligand.
  • the isolated nucleic acid molecule encodes a TIE-2 ligand of the TIE family of ligands, whose representatives comprise ligands TL1, TL2, TL3 and TL4 as described herein, which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor.
  • the isolated nucleic acid molecule encodes a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first.
  • the first TIE-2 ligand is TL1 and the second TIE-2 ligand is TL2.
  • the invention envisions other combinations using additional TIE-2 ligand family members.
  • the isolated nucleic acid molecule encodes a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising a portion of a first ligand selected from the group consisting of TL1, TL2, TL3 and TL4, and a portion of a second ligand, different from the first ligand, selected from the group consisting of TL1, TL2, TL3 and TL4.
  • the isolated nucleic acid may be DNA, cDNA or RNA.
  • the invention also provides for a vector comprising an isolated nucleic acid molecule encoding a modified TIE-2 ligand.
  • the invention further provides for a host-vector system for the production in a suitable host cell of a polypeptide having the biological activity of a modified TIE-2 ligand.
  • the suitable host cell may be bacterial, yeast, insect or mammalian.
  • the invention also provides for a method of producing a polypeptide having the biological activity of a modified TIE-2 ligand which comprises growing cells of the host-vector system under conditions permitting production of the polypeptide and recovering the polypeptide so produced.
  • the invention herein described of an isolated nucleic acid molecule encoding a modified TIE-2 ligand further provides for the development of the ligand as a therapeutic for the treatment of patients suffering from disorders involving cells, tissues or organs which express the TIE-2 receptor.
  • the present invention also provides for an antibody which specifically binds such a therapeutic molecule.
  • the antibody may be monoclonal or polyclonal.
  • the invention also provides for a method of using such a monoclonal or polyclonal antibody to measure the amount of the therapeutic molecule in a sample taken from a patient for purposes of monitoring the course of therapy.
  • the present invention also provides for an antibody which specifically binds a modified TIE-2 ligand as described herein.
  • the antibody may be monoclonal or polyclonal.
  • the invention further provides for therapeutic compositions comprising an antibody which specifically binds a modified TIE-2 ligand, in a pharmaceutically acceptable vehicle.
  • the invention also provides for a method of blocking blood vessel growth in a mammal by administering an effective amount of a therapeutic composition comprising an antibody which specifically binds a receptor activating modified TIE-2 ligand as described herein, in a pharmaceutically acceptable vehicle.
  • the invention further provides for therapeutic compositions comprising a modified TIE-2 ligand as described herein, in a pharmaceutically acceptable vehicle.
  • the invention also provides for a method of promoting neovascularization in a patient by administering an effective amount of a therapeutic composition comprising a receptor activating modified TIE-2 ligand as described herein, in a pharmaceutically acceptable vehicle.
  • the method may be used to promote wound healing.
  • the method may be used to treat ischemia.
  • a receptor activating modified TIE-2 ligand as described herein is used, alone or in combination with other hematopoietic factors, to promote the proliferation or differentiation of hematopoietic stem cells, B cells or megakaryocytic cells.
  • the invention provides that a modified TIE-2 ligand may be conjugated to a cytotoxic agent and a therapeutic composition prepared therefrom.
  • the invention further provides for a receptorbody which specifically binds a modified TIE-2 ligand.
  • the invention further provides for therapeutic compositions comprising a receptorbody which specifically binds a modified TIE-2 ligand in a pharmaceutically acceptable vehicle.
  • the invention also provides for a method of blocking blood vessel growth in a mammal by administering an effective amount of a therapeutic composition comprising a receptorbody which specifically binds a modified TIE-2 ligand in a pharmaceutically acceptable vehicle.
  • the invention also provides for a TIE-2 receptor antagonist as well as a method of inhibiting TIE-2 biological activity in a mammal comprising administering to the mammal an effective amount of a TIE-2 antagonist.
  • the antagonist may be a modified TIE-2 ligand as described herein which binds to, but does not activate, the TIE-2 receptor.
  • FIGS. 1 A and 1 B TIE-2 receptorbody (TIE-2 RB) inhibits the development of blood vessels in the embryonic chicken chorioallantoic membrane (CAM).
  • FIG. 1 A embryos treated with EHK-1 RB (rEHK-1 ecto/hIgG1 Fc) were viable and possessed normally developed blood vessels in their surrounding CAM.
  • FIG. 1 B all embryos treated with TIE-2 RB (r TIE-2 ecto/h IgG1 Fc) were dead, diminished in size and were almost completely devoid of surrounding blood vessels.
  • FIG. 2 Vector pJFE14.
  • FIG. 3 Restriction map of ⁇ gt10.
  • FIGS. 4 A- 4 D Nucleic acid and deduced amino acid (single letter code) sequences of human TIE-2 ligand 1 from clone ⁇ gt10 encoding htie-2 ligand 1 (SEQ. ID. NO. 1 and SEQ. ID. NO. 2).
  • FIGS. 5 A- 5 D Nucleic acid and deduced amino acid (single letter code) sequences of human TIE-2 ligand 1 from T98G clone (SEQ. ID. NO. 3 and SEQ. ID. NO. 4).
  • FIGS. 6 A- 6 D Nucleic acid and deduced amino acid (single letter code) sequences of human TIE-2 ligand 2 from clone pBluescript KS encoding human TIE 2 ligand 2 (SEQ. ID. NO. 5 and SEQ. ID. NO. 6).
  • FIG. 7 Western blot showing activation of TIE-2 receptor by TIE-2 ligand 1 (Lane L1) but not by TIE-2 ligand 2 (Lane L2) or control (Mock).
  • FIG. 8 Western blot showing that prior treatment of HAEC cells with excess TIE-2 ligand 2 (Lane 2) antagonizes the subsequent ability of dilute TIE-2 ligand 1 to activate the TIE-2 receptor (TIE2-R) as compared with prior treatment of HAEC cells with MOCK medium (Lane 1).
  • FIG. 9 Western blot demonstrating the ability of TL2 to competitively inhibit TL1 activation of the TIE-2 receptor using the human cell hybrid line, EA.hy926.
  • FIGS. 10 A- 10 D Histogram representation of binding to rat TIE-2 IgG immobilized surface by TIE-2 ligand in C2C12 ras (FIG. 10 A), Rat2 ras (FIG. 10 B), SHEP (FIG. 10 C), and T98G (FIG. 10D) concentrated (10 ⁇ ) conditioned medium.
  • Rat TIE-2 (rTIE2) specific binding is demonstrated by the significant reduction in the binding activity in the presence of 25 ⁇ g/ml soluble rat TIE-2 RB as compared to a minor reduction in the presence of soluble trkB RB.
  • FIGS. 11 A- 11 B Binding of recombinant human TIE-2 ligand 1 (hTL1) (FIG. 11A) and human TIE-2 ligand 2 (hTL2) (FIG. 11 B), in COS cell supernatants, to a human TIE-2 receptorbody (RB) immobilized surface.
  • Human TIE-2-specific binding was determined by incubating the samples with 25 ⁇ g/ml of either soluble human TIE-2 RB or trkB RB; significant reduction in the binding activity is observed only for the samples incubated with human TIE-2 RB.
  • FIG. 12 Western blot showing that TIE-2 receptorbody (denoted TIE-2 RB or, as here, TIE2-Fc) blocks the activation of TIE-2 receptors by TIE-2 ligand 1 (TL1) in HUVEC cells, whereas an unrelated receptorbody (TRKB-Fc) does not block this activation.
  • TIE-2 receptorbody denoted TIE-2 RB or, as here, TIE2-Fc
  • TIE-2 ligand 1 TL1
  • TRKB-Fc unrelated receptorbody
  • FIG. 13 Agarose gels showing serial dilutions [undiluted (1) to 10 4 ] of the TL1 and TL2 RT-PCR products obtained from E14.5 mouse fetal liver (Lanes 1-total, Lanes 3-stromal enriched, and Lanes 4-c-kit + TER119 hematopoietic precursor cells) and E14.5 mouse fetal thymus (Lanes 2-total).
  • FIG. 14 Agarose gels showing serial dilutions [undiluted (1) to 10 3 ] of the TL1 and TL2 RT-PCR products obtained from E17.5 mouse fetal thymus cortical stromal cells (Lanes 1-CDR1+/A2B5- ⁇ ) and medullary stromal cells (Lane CDR1-/A2B5+).
  • FIG. 15 A schematic representation of the hypothesized role of the TIE-2/T1E ligands in angiogenesis.
  • TL1 is represented by (•)
  • TL2 is represented by (*)
  • TIE-2 is represented by (T)
  • VEGF is represented by ([])
  • flk-1 a VEGF receptor
  • FIG. 16 In situ hybridization slides showing the temporal expression pattern of TIE-2, TL1, TL2, and VEGF during angiogenesis associated with follicular development and corpus luteum formation in the ovary of a rat that was treated with pregnant mare serum.
  • Column 1 Early pre-ovulatory follicle;
  • Column 2 pre-ovulatory follicle;
  • Column 3 early corpus luteum;
  • Column 4 atretic follicle; Row A: bright field;
  • Row B VEGF; Row C: TL2; Row D: TL1 and Row E: TIE-2 receptor.
  • FIG. 17 Comparison of amino acid sequences of mature TL1 protein (SEQ. ID. NO. 7) and mature TL2 protein (SEQ. ID. NO. 8).
  • the TL1 sequence is the same as that set forth in FIGS. 4A-4D (SEQ. ID. NO. 1 and SEQ. ID. NO. 2), except that the putative leader sequence has been removed.
  • the TL2 sequence is the same as that set forth in FIGS. 6A-6D (SEQ. ID. NO. 5 and SEQ. ID. NO. 6), except that the putative leader sequence has been removed.
  • FIG. 18 Western blot of the covalent multimeric structure of TL1 and TL2 (Panel A) and the interconversion of TL1 and TL2 by the mutation of one cysteine (Panel B).
  • FIG. 19 A typical curve of TIE-2-IgG binding to immobilized TL1 in a quantitative cell-free binding assay.
  • FIG. 20 A typical curve showing TIE-2 ligand 1 ligandbody comprising the fibrinogen-like domain of the ligand bound to the Fc domain of IgG (TL1-fFc) binding to immobilized TIE-2 ectodomain in a quantitative cell-free binding assay.
  • FIGS. 21 A- 21 C Nucleotide and deduced amino acid (single letter code) sequences of TIE ligand-3 (SEQ. ID. NO. 9 and SEQ. ID. NO. 10).
  • the coding sequence starts at position 47.
  • the fibrinogen-like domain starts at position 929.
  • FIGS. 22 A- 22 B Comparison of Amino Acid Sequences of TIE Ligand Family Members.
  • the boxed regions indicate conserved regions of homology among the family members.
  • FIGS. 23 A- 23 C Nucleotide and deduced amino acid (single letter code) sequences of TIE ligand-4 (SEQ. ID. NO. 17 and SEQ. ID. NO. 18). Arrow indicates nucleotide position 569.
  • FIGS. 24 A- 24 C Nucleotide and deduced amino acid (single letter code) sequences of chimeric TIE ligand designated 1N1C2F (chimera 1) (SEQ. ID. NO. 19 and SEQ. ID. NO. 20). The putative leader sequence is encoded by nucleotides 1-60.
  • FIGS. 25 A- 25 C Nucleotide and deduced amino acid (single letter code) sequences of chimeric TIE ligand designated 2N2C1F (chimera 2) (SEQ. ID. NO. 21 and SEQ. ID. NO. 22).
  • the putative leader sequence is encoded by nucleotides 1-48.
  • FIGS. 26 A- 26 C Nucleotide and deduced amino acid (single letter code) sequences of chimeric TIE ligand designated 1N2C2F (chimera 3) (SEQ. ID. NO. 23 and SEQ. ID. NO. 24).
  • the putative leader sequence is encoded by nucleotides 1-60.
  • FIGS. 27 A- 27 C Nucleotide and deduced amino acid (single letter code) sequences of chimeric TIE ligand designated 2N1C1F (chimera 4) (SEQ. ID. NO. 25 and SEQ. ID. NO. 26).
  • the putative leader sequence is encoded by nucleotides 1-48.
  • modified TIE-2 ligand refers to a ligand of the TIE family of ligands, whose representatives comprise ligands TL1, TL2, TL3 and TL4 as described herein, which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor.
  • Modified TIE-2 ligand also includes a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first.
  • the first TIE-2 ligand is TL1
  • the second TIE-2 ligand is TL2.
  • the invention envisions other combinations using additional TIE-2 ligand family members.
  • the first ligand is selected from the group consisting of TL1, TL2, TL3 and TL4, and the second ligand, different from the first ligand, is selected from the group consisting of TL1, TL2, TL3 and TL4.
  • the invention also provides for an isolated nucleic acid molecule encoding a modified TIE-2 ligand.
  • the isolated nucleic acid molecule encodes a TIE-2 ligand of the TIE family of ligands, whose representatives comprise ligands TL1, TL2, TL3 and TL4 as described herein, which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor.
  • the isolated nucleic acid molecule encodes a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first.
  • the first TIE-2 ligand is TL1 and the second TIE-2 ligand is TL2.
  • the invention envisions other combinations using additional TIE-2 ligand family members.
  • the isolated nucleic acid molecule encodes a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising a portion of a first ligand selected from the group consisting of TL1, TL2, TL3 and TL4, and a portion of a second ligand, different from the first ligand, selected from the group consisting of TL1, TL2, TL3 and TL4.
  • the present invention comprises the modified TIE-2 ligands and their amino acid sequences, as well as functionally equivalent variants thereof, as well as proteins or peptides comprising substitutions, deletions or insertional mutants of the described sequences, which bind TIE-2 receptor and act as agonists or antagonists thereof.
  • Such variants include those in which amino acid residues are substituted for residues within the sequence resulting in a silent change.
  • one or more amino acid residues within the sequence can be substituted by another amino acid(s) of a similar polarity which acts as a functional equivalent, resulting in a silent alteration.
  • Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
  • the class of nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
  • the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
  • the positively charged (basic) amino acids include arginine, lysine and histidine.
  • the negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
  • proteins or fragments or derivatives thereof which exhibit the same or similar biological activity as the modified TIE-2 ligands described herein, and derivatives which are differentially modified during or after translation, e.g., by glycosylation, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc.
  • Functionally equivalent molecules also include molecules that contain modifications, including N-terminal modifications, which result from expression in a particular recombinant host, such as, for example, N-terminal methylation which occurs in certain bacterial (e.g E. coli ) expression systems.
  • the present invention also encompasses the nucleotide sequences that encode the proteins described herein as modified TIE-2 ligands, as well as host cells, including yeast, bacteria, viruses, and mammalian cells, which are genetically engineered to produce the proteins, by e.g. transfection, transduction, infection, electroporation, or microinjection of nucleic acid encoding the modified TIE-2 ligands described herein in a suitable expression vector.
  • the present invention also encompasses introduction of the nucleic acid encoding modified TIE-2 ligands through gene therapy techniques such as is described, for example, in Finkel and Epstein FASEB J. 9:843-851 (1995); Guzman, et al. PNAS (USA) 91:10732-10736 (1994).
  • the present invention encompasses DNA and RNA sequences that hybridize to a modified TIE-2 ligand encoding nucleotide sequence, under conditions of moderate stringency, as defined in, for example, Sambrook, et al. Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1, pp. 101-104, Cold Spring Harbor Laboratory Press (1989).
  • a nucleic acid molecule contemplated by the invention includes one having a nucleotide sequence deduced from an amino acid sequence of a modified TIE-2 ligand prepared as described herein, as well as a molecule having a sequence of nucleotides that hybridizes to such a nucleotide sequence, and also a nucleotide sequence which is degenerate of the above sequences as a result of the genetic code, but which encodes a ligand that binds TIE-2 receptor and which has an amino acid sequence and other primary, secondary and tertiary characteristics that are sufficiently duplicative of a modified TIE-2 ligand described herein so as to confer on the molecule the same biological activity as the modified TIE-2 ligand described herein.
  • the present invention provides for an isolated nucleic acid molecule encoding a modified TIE-2 ligand that binds and activates TIE-2 receptor comprising a nucleotide sequence encoding TIE-2 ligand 1 wherein the portion of the nucleotide sequence that encodes the N-terminal domain of TIE-2 ligand 1 is replaced by a nucleotide sequence that encodes the N-terminal domain of TIE-2 ligand 2.
  • the invention also provides for such a nucleic acid molecule, with a further modification such that the portion of the nucleotide sequence that encodes the coiled-coil domain of TIE-2 ligand 1 is replaced by a nucleotide sequence that encodes the coiled-coil domain of TIE-2 ligand 2.
  • the present invention also provides for an isolated nucleic acid molecule encoding a modified TIE-2 ligand that binds and activates TIE-2 receptor comprising a nucleotide sequence encoding TIE-2 ligand 1 wherein the portion of the nucleotide sequence that encodes the N-terminal domain of TIE-2 ligand 1 is replaced by a nucleotide sequence that encodes the N-terminal domain of TIE-2 ligand 2 and which is further modified to encode a different amino acid instead of the cysteine residue encoded by nucleotides 784-787 as set forth in FIGS. 27A-27C (SEQ. ID. NO. 25 and SEQ. ID. NO. 26).
  • a serine residue is preferably substituted for the cysteine residue.
  • the nucleic acid molecule is further modified to encode a different amino acid instead of the arginine residue encoded by nucleotides 199-201 as set forth in FIGS. 27A-27C (SEQ. ID. NO. 25 and SEQ. ID. NO. 26).
  • a serine residue is preferably substituted for the arginine residue.
  • the present invention also provides for an isolated nucleic acid molecule encoding a modified TIE-2 ligand that binds and activates TIE-2 receptor comprising a nucleotide sequence encoding TIE-2 ligand 1 which is modified to encode a different amino acid instead of the cysteine residue at amino acid position 245.
  • a serine residue is preferably substituted for the cysteine residue.
  • the invention further provides for an isolated nucleic acid molecule encoding a modified TIE-2 ligand that binds but does not activate TIE-2 receptor comprising a nucleotide sequence encoding TIE-2 ligand 1 wherein the portion of the nucleotide sequence that encodes the N-terminal domain of TIE-2 ligand 1 is deleted.
  • the invention also provides for such a nucleic acid molecule further modified so that the portion of the nucleotide sequence that encodes the coiled-coil domain of TIE-2 ligand 1 is deleted and the portion encoding the fibrinogen-like domain is fused in-frame to a nucleotide sequence encoding a human immunoglobulin gamma-1 constant region (IgG1 Fc).
  • the invention further provides for an isolated nucleic acid molecule encoding a modified TIE-2 ligand that binds but does not activate TIE-2 receptor comprising a nucleotide sequence encoding TIE-2 ligand 2 wherein the portion of the nucleotide sequence that encodes the N-terminal domain of TIE-2 ligand 2 is deleted.
  • the invention also provides for such a nucleic acid molecule further modified so that the portion of the nucleotide sequence that encodes the coiled-coil domain of TIE-2 ligand 2 is deleted and the portion encoding the fibrinogen-like domain is fused in-frame to a nucleotide sequence encoding a human immunoglobulin gamma-1 constant region (IgG1 Fc).
  • the invention further provides for an isolated nucleic acid molecule encoding a modified TIE-2 ligand that binds but does not activate TIE-2 receptor comprising a nucleotide sequence encoding TIE-2 ligand 1 wherein the portion of the nucleotide sequence that encodes the fibrinogen-like domain of TIE-2 ligand 1 is replaced by a nucleotide sequence that encodes the fibrinogen-like domain of TIE-2 ligand 2.
  • the invention also provides for such a nucleic acid molecule further modified so that the portion of the nucleotide sequence that encodes the coiled-coil domain of TIE-2 ligand 1 is replaced by a nucleotide sequence that encodes the coiled-coil domain of TIE-2 ligand 2.
  • the invention further provides for a modified TIE-2 ligand encoded by any of nucleic acid molecules of the invention.
  • the present invention also provides for a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first, wherein the first and second TIE-2 ligands are selected from the group consisting of TIE-2 Ligand-1, TIE-2 Ligand-2, TIE Ligand-3 and TIE Ligand-4.
  • the chimeric TIE ligand comprises at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2.
  • the invention also provides a nucleic acid molecule that encodes a chimeric TIE ligand as set forth in FIGS. 24A-24C (SEQ. ID. NO. 19 and SEQ. ID. NO. 20), 25 A- 25 C (SEQ. ID. NO. 21 and SEQ. ID. NO. 22), 26 A- 26 C (SEQ. ID. NO. 23 and SEQ. ID. NO. 24), or 27 A- 27 C (SEQ. ID. NO. 25 and SEQ. ID. NO. 26).
  • the invention also provides a chimeric TIE ligand as set forth in FIGS. 24A-24C (SEQ. ID. NO. 19 and SEQ. ID. NO. 20), 25 A- 25 C (SEQ. ID. NO. 21 and SEQ. ID.
  • the invention further provides a chimeric TIE ligand as set forth in FIGS. 27A-27C (SEQ. ID. NO. 25 and SEQ. ID. NO. 26), modified to have a different amino acid instead of the cysteine residue encoded by nucleotides 784-787.
  • any of the methods known to one skilled in the art for the insertion of DNA fragments into a vector may be used to construct expression vectors encoding a modified TIE-2 ligand using appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinations (genetic recombination). Expression of a nucleic acid sequence encoding a modified TIE-2 ligand or peptide fragments thereof may be regulated by a second nucleic acid sequence which is operably linked to the a modified TIE-2 ligand encoding sequence such that the modified TIE-2 ligand protein or peptide is expressed in a host transformed with the recombinant DNA molecule.
  • expression of a modified TIE-2 ligand described herein may be controlled by any promoter/enhancer element known in the art.
  • Promoters which may be used to control expression of the ligand include, but are not limited to the long terminal repeat as described in Squinto et al., (Cell 65:1-20 (1991)); the SV40 early promoter region (Bernoist and Chambon, Nature 290:304-310), the CMV promoter, the M-MuLV 5′ terminal repeat, the promoter contained in the 3′ long terminal repeat of Rous sarcoma virus (Yamamoto, et al., Cell 22:787-797 (1980)), the herpes thymidine kinase promoter (Wagner et al., Proc.
  • promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADH (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals; elastase I gene control region which is active in pancreatic acinar cells (Swift et al., Cell 38:639-646 (1984); Ornitz et al., Cold Spring Harbor Symp. Quant. Biol.
  • mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58); alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al, 1987, Genes and Devel.
  • beta-globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94); myelin basic protein gene control region which is active in oligodendrocytes in the brain (Readhead et al., 1987, Cell 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Shani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).
  • the invention further encompasses the production of antisense compounds which are capable of specifically hybridizing with a sequence of RNA encoding a modified TIE-2 ligand to modulate its expression. Ecker, U.S. Pat. No. 5,166,195, issued Nov. 24, 1992.
  • expression vectors capable of being replicated in a bacterial or eukaryotic host comprising a nucleic acid encoding a modified TIE-2 ligand as described herein, are used to transfect a host and thereby direct expression of such nucleic acid to produce a modified TIE-2 ligand, which may then be recovered in a biologically active form.
  • a biologically active form includes a form capable of binding to TIE receptor and causing a biological response such as a differentiated function or influencing the phenotype of the cell expressing the receptor. Such biologically active forms could, for example, induce phosphorylation of the tyrosine kinase domain of TIE receptor.
  • the biological activity may be an effect as an antagonist to the TIE receptor.
  • the active form of a modified TIE-2 ligand is one that can recognize TIE receptor and thereby act as a targeting agent for the receptor for use in both diagnostics and therapeutics. In accordance with such embodiments, the active form need not confer upon any TIE expressing cell any change in phenotype.
  • Expression vectors containing the gene inserts can be identified by four general approaches: (a) DNA-DNA hybridization, (b) presence or absence of “marker” gene functions, (c) expression of inserted sequences and (d) PCR detection.
  • the presence of a foreign gene inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising sequences that are homologous to an inserted modified TIE-2 ligand encoding gene.
  • the recombinant vector/host system can be identified and selected based upon the presence or absence of certain “marker” gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if a nucleic acid encoding a modified TIE-2 ligand is inserted within the marker gene sequence of the vector, recombinants containing the insert can be identified by the absence of the marker gene function.
  • recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant.
  • Such assays can be based, for example, on the physical or functional properties of a modified TIE-2 ligand gene product, for example, by binding of the ligand to TIE receptor or a portion thereof which may be tagged with, for example, a detectable antibody or portion thereof or by binding to antibodies produced against the modified TIE-2 ligand protein or a portion thereof.
  • Cells of the present invention may transiently or, preferably, constitutively and permanently express a modified TIE-2 ligand as described herein.
  • DNA nucleotide primers can be prepared corresponding to a tie specific DNA sequence. These primers could then be used to PCR a tie gene fragment. (PCR Protocols: A Guide To Methods and Applications, Edited by Michael A. Innis et al., Academic Press (1990)).
  • the recombinant ligand may be purified by any technique which allows for the subsequent formation of a stable, biologically active protein.
  • the ligand is secreted into the culture medium from which it is recovered.
  • the ligand may be recovered from cells either as soluble: proteins or as inclusion bodies, from which it may be extracted quantitatively by 8M guanidinium hydrochloride and dialysis in accordance with well known methodology.
  • affinity chromatography conventional ion exchange chromatography, hydrophobic interaction chromatography, reverse phase chromatography or gel filtration may be used.
  • a modified TIE-2 ligand encoding gene may be used to inactivate or “knock out” an endogenous gene by homologous recombination, and thereby create a TIE ligand deficient cell, tissue, or animal.
  • the recombinant TIE ligand-4 encoding gene may be engineered to contain an insertional mutation, for example the neo gene, which would inactivate the native TIE ligand-4 encoding gene.
  • Such a construct under the control of a suitable promoter, may be introduced into a cell, such as an embryonic stem cell, by a technique such as transfection, transduction, or injection.
  • Cells containing the construct may then be selected by G418 resistance.
  • Cells which lack an intact TIE ligand-4 encoding gene may then be identified, e.g. by Southern blotting, PCR detection, Northern blotting or assay of expression.
  • Cells lacking an intact TIE ligand-4 encoding gene may then be fused to early embryo cells to generate transgenic animals deficient in such ligand. Such an animal may be used to define specific in vivo processes, normally dependent upon the ligand.
  • the present invention also provides for antibodies to a modified TIE-2 ligand described herein which are useful for detection of the ligand in, for example, diagnostic applications.
  • a modified TIE-2 ligand described herein which are useful for detection of the ligand in, for example, diagnostic applications.
  • any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used.
  • the monoclonal antibodies may be human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies.
  • Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:7308-25 7312; Kozbor et al., 1983, Immunology Today 4:72-79; Olsson et al., 1982, Meth. Enzymol. 92:3-16).
  • Chimeric antibody molecules may be prepared containing a mouse antigen-binding domain with human constant regions (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851, Takeda et al., 1985, Nature 314:452).
  • Various procedures known in the art may be used for the production of polyclonal antibodies to epitopes of a modified TIE-2 ligand described herein.
  • various host animals including but not limited to rabbits, mice and rats can be immunized by injection with a modified TIE-2 ligand, or a fragment or derivative thereof.
  • adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG ( Bacille Calmette-Guerin ) and Corynebacterium parvum.
  • BCG Bacille Calmette-Guerin
  • a molecular clone of an antibody to a selected a modified TIE-2 ligand epitope can be prepared by known techniques. Recombinant DNA methodology (see e.g, Maniatis et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) may be used to construct nucleic acid sequences which encode a monoclonal antibody molecule, or antigen binding region thereof.
  • Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
  • fragments include but are not limited to: the F(ab′) 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab′ fragments which can be generated by reducing the disulfide bridges of the F(ab′) 2 fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.
  • Antibody molecules may be purified by known techniques, e.g., immunoabsorption or immunoaffinity chromatography, chromatographic methods such as HPLC (high performance liquid chromatography), or a combination thereof.
  • the present invention further encompasses an immunoassay for measuring the amount of a modified TIE-2 ligand in a biological sample by
  • the invention further encompasses an assay for measuring the amount of TIE receptor in a biological sample by
  • the present invention also provides for the utilization of a modified TIE-2 ligand which activates the TIE-2 receptor as described herein, to support the survival and/or growth and/or migration and/or differentiation of TIE-2 receptor expressing cells.
  • the ligand may be used as a supplement to support, for example, endothelial cells in culture.
  • a modified TIE-2 ligand for the TIE-2 receptor enables the utilization of assay systems useful for the identification of agonists or antagonists of the TIE-2 receptor.
  • assay systems would be useful in identifying molecules capable of promoting or inhibiting angiogenesis.
  • antagonists of the TIE-2 receptor may be identified as test molecules that are capable of interfering with the interaction of the TIE-2 receptor with a modified TIE-2 ligand that binds the TIE-2 receptor.
  • Such antagonists are identified by their ability to 1) block the binding of a biologically active modified TIE-2 ligand to the receptor as measured, for example, using BlAcore biosensor technology (BlAcore; Pharmacia Biosensor, Piscataway, N.J.); or 2) block the ability of a biologically active modified TIE-2 ligand to cause a biological response.
  • BlAcore biosensor technology BlAcore; Pharmacia Biosensor, Piscataway, N.J.
  • Such biological responses include, but are not limited to, phosphorylation of the TIE receptor or downstream components of the TIE signal transduction pathway, or survival, growth or differentiation of TIE receptor bearing cells.
  • cells engineered to express the TIE receptor may be dependent for growth on the addition of a modified TIE-2 ligand.
  • Such cells provide useful assay systems for identifying additional agonists of the TIE receptor, or antagonists capable of interfering with the activity of the modified TIE-2 ligand on such cells.
  • autocrine cells engineered to be capable of co-expressing both a modified TIE-2 ligand and receptor, may provide useful systems for assaying potential agonists or antagonists.
  • the present invention provides for introduction of a TIE-2 receptor into cells that do not normally express this receptor, thus allowing these cells to exhibit profound and easily distinguishable responses to a ligand which binds this receptor.
  • the type of response elicited depends on the cell utilized, and not the specific receptor introduced into the cell.
  • Appropriate cell lines can be chosen to yield a response of the greatest utility for assaying, as well as discovering, molecules that can act on tyrosine kinase receptors.
  • the molecules may be any type of molecule, including but not limited to peptide and non-peptide molecules, that will act in systems to be described in a receptor specific manner.
  • TIE receptor or a chimeric receptor comprising the extracellular domain of another receptor tyrosine kinase such as, for example, trkC and the intracellular domain of a TIE receptor
  • a fibroblast cell line e.g., NIH3T3 cells
  • Such cells may be further engineered to express a modified TIE-2 ligand, thus creating an autocrine system useful for assaying for molecules that act as antagonists/agonists of this interaction.
  • the present invention provides for host cells comprising nucleic acid encoding a modified TIE-2 ligand and nucleic acid encoding TIE receptor.
  • the TIE receptor/modified TIE-2 ligand interaction also provides a useful system for identifying small molecule agonists or antagonists of the TIE receptor. For example, fragments, mutants or derivatives of a modified TIE-2 ligand may be identified that bind TIE receptor but do not induce any other biological activity. Alternatively, the characterization of a modified TIE-2 ligand enables the further characterization of active portions of the molecule. Further, the identification of a ligand enables the determination of the X-ray crystal structure of the receptor/ligand complex, thus enabling identification of the binding site on the receptor. Knowledge of the binding site will provide useful insight into the rational design of novel agonists and antagonists.
  • test molecule binding may be measured in a number of ways.
  • the actual binding of test molecule to cells expressing TIE may be detected or measured, by detecting or measuring (i) test molecule bound to the surface of intact cells; (ii) test molecule cross-linked to TIE protein in cell lysates; or (iii) test molecule bound to TIE in vitro.
  • test molecule bound to TIE may be evaluated by using reagents that demonstrate the unique properties of that interaction.
  • the methods of the invention may be used as follows.
  • a modified TIE-2 ligand in a sample is to be measured. Varying dilutions of the sample (the test molecule), in parallel with a negative control (NC) containing no modified TIE-2 ligand activity, and a positive control (PC) containing a known amount of a modified TIE-2 ligand, may be exposed to cells that express TIE in the presence of a detectably labeled modified TIE-2 ligand (in this example, radioiodinated ligand).
  • a detectably labeled modified TIE-2 ligand in this example, radioiodinated ligand
  • the amount of modified TIE-2 ligand in the test sample may be evaluated by determining the amount of 125 I-labeled modified TIE-2 ligand that binds to the controls and in each of the dilutions, and then comparing the sample values to a standard curve. The more modified TIE-2 ligand in the sample, the less 125 I-ligand that will bind to TIE.
  • the amount of 125 I-ligand bound may be determined by measuring the amount of radioactivity per cell, or by cross-linking a modified TIE-2 ligand to cell surface proteins using DSS, as described in Meakin and Shooter, 1991, Neuron 6:153-163, and detecting the amount of labeled protein in cell extracts using, for example, SDS polyacrylamide gel electrophoresis, which may reveal a labeled protein having a size corresponding to TIE receptor/modified TIE-2 ligand.
  • test molecule/TIE interaction may further be tested by adding to the assays various dilutions of an unlabeled control ligand that does not bind the TIE receptor and therefore should have no substantial effect on the competition between labeled modified TIE-2 ligand and test molecule for TIE binding.
  • a molecule known to be able to disrupt TIE receptor/modified TIE-2 ligand binding such as, but not limited to, anti-TIE antibody, or TIE receptorbody as described herein, may be expected to interfere with the competition between 125 I-modified TIE-2 ligand and test molecule for TIE receptor binding.
  • Detectably labeled modified TIE-2 ligand includes, but is not limited to, a modified TIE-2 ligand linked covalently or noncovalently to a radioactive substance, a fluorescent substance, a substance that has enzymatic activity, a substance that may serve as a substrate for an enzyme (enzymes and substrates associated with calorimetrically detectable reactions are preferred) or to a substance that can be recognized by an antibody molecule that is preferably a detectably labeled antibody molecule.
  • the specific binding of test molecule to TIE may be measured by evaluating the secondary biological effects of a modified TIE-2 ligand/TIE receptor binding, including, but not limited to, cell growth and/or differentiation or immediate early gene expression or phosphorylation of TIE.
  • a modified TIE-2 ligand/TIE receptor binding including, but not limited to, cell growth and/or differentiation or immediate early gene expression or phosphorylation of TIE.
  • the ability of the test molecule to induce differentiation can be tested in cells that lack tie and in comparable cells that express tie; differentiation in tie-expressing cells but not in comparable cells that lack tie would be indicative of a specific test molecule/TIE interaction.
  • a similar analysis could be performed by detecting immediate early gene (e.g. fos and jun) induction in tie-minus and tie-plus cells, or by detecting phosphorylation of TIE using standard phosphorylation assays known in the art. Such analysis might be useful in identifying agonists or antagonists that do not competitively bind to TIE.
  • the present invention provides for a method of identifying a molecule that has the biological activity of a modified TIE-2 ligand comprising (i) exposing a cell that expresses tie to a test molecule and (ii) detecting the specific binding of the test molecule to TIE receptor, in which specific binding to TIE positively correlates with TIE-like activity.
  • Specific binding may be detected by either assaying for direct binding or the secondary biological effects of binding, as discussed supra.
  • Such a method may be particularly useful in identifying new members of the TIE ligand family or, in the pharmaceutical industry, in screening a large array of peptide and non-peptide molecules (e.g., peptidomimetics) for TIE associated biological activity.
  • a large grid of culture wells may be prepared that contain, in alternate rows, PC12 (or fibroblasts, see infra) cells that are either tie-minus or engineered to be tie-plus.
  • PC12 or fibroblasts, see infra
  • a variety of test molecules may then be added such that each column of the grid, or a portion thereof, contains a different test molecule.
  • Each well could then be scored for the presence or absence of growth and/or differentiation. An extremely large number of test molecules could be screened for such activity in this manner.
  • the invention provides for methods of detecting or measuring TIE ligand-like activity or identifying a molecule as having such activity comprising (i) exposing a test molecule to a TIE receptor protein in vitro under conditions that permit binding to occur and (ii) detecting binding of the test molecule to the TIE receptor protein, in which binding of test molecule to TIE receptor correlates with TIE ligand-like activity.
  • the TIE receptor may or may not be substantially purified, may be affixed to a solid support (e.g. as an affinity column or as an ELISA assay), or may be incorporated into an artificial membrane. Binding of test molecule to TIE receptor may be evaluated by any method known in the art. In preferred embodiments, the binding of test molecule may be detected or measured by evaluating its ability to compete with detectably labeled known TIE ligands for TIE receptor binding.
  • the present invention also provides for a method of detecting the ability of a test molecule to function as an antagonist of TIE ligand-like activity comprising detecting the ability of the molecule to inhibit an effect of TIE ligand binding to TIE receptor on a cell that expresses the receptor.
  • Such an antagonist may or may not interfere with TIE receptor/modified TIE-2 ligand binding.
  • Effects of a modified TIE-2 ligand binding to TIE receptor are preferably biological or biochemical effects, including, but not limited to, cell survival or proliferation, cell transformation, immediate early gene induction, or TIE phosphorylation.
  • the invention further provides for both a method of identifying antibodies or other molecules capable of neutralizing the ligand or blocking binding to the receptor, as well as the molecules identified by the method.
  • the method may be performed via an assay which is conceptually similar to an ELISA assay.
  • TIE receptorbody may be bound to a solid support, such as a plastic multiwell plate.
  • a known amount of a modified TIE-2 ligand which has been Myc-tagged may then be introduced to the well and any tagged modified TIE-2 ligand which binds the receptorbody may then be identified by means of a reporter antibody directed against the Myc-tag.
  • This assay system may then be used to screen test samples for molecules which are capable of i) binding to the tagged ligand or ii) binding to the receptorbody and thereby blocking binding to the receptorbody by the tagged ligand.
  • a test sample containing a putative molecule of interest together with a known amount of tagged ligand may be introduced to the well and the amount of tagged ligand which binds to the receptorbody may be measured.
  • samples containing molecules which are capable of blocking ligand binding to the receptor may be identified.
  • the molecules of interest thus identified may be isolated using methods well known to one of skill in the art.
  • a blocker of ligand binding is found, one of skill in the art would know to perform secondary assays to determine whether the blocker is binding to the receptor or to the ligand, as well as assays to determine if the blocker molecule can neutralize the biological activity of the ligand.
  • a binding assay which employs BlAcore biosensor technology (or the equivalent), in which either TIE receptorbody or a modified TIE-2 ligand or ligandbody is covalently attached to a solid support (e.g. carboxymethyl dextran on a gold surface)
  • a solid support e.g. carboxymethyl dextran on a gold surface
  • the blocker molecule can neutralize the biological activity of the ligand, one of skill in the art could perform a phosphorylation assay (see Example 5) or alternatively, a functional bioassay, such as a survival assay, by using primary cultures of, for example, endothelial cells.
  • a blocker molecule which binds to the receptorbody could be an agonist and one of skill in the art would know to how to determine this by performing an appropriate assay for identifying additional agonists of the TIE receptor.
  • TIE-2 ligand 1 contains a “coiled coil” domain (beginning at the 5′ end and extending to the nucleotide at about position 1160 of FIGS. 4A-4D (SEQ. ID. NO. 1 and SEQ. ID. NO. 2) and about position 1157 of FIGS. 5A-5D (SEQ. ID. NO. 3 and SEQ. ID. NO. 4)) and a fibrinogen-like domain (which is encoded by the nucleotide sequence of FIGS. 4A-4D (SEQ. ID. NO. 1 and SEQ. ID. NO.
  • TIE-2 ligand 2 is believed to begin on or around the same amino acid sequence as in ligand 1 (FRDCA) which is encoded by nucleotides beginning around 1197 of FIGS. 6A-6D (SEQ. ID. NO. 5 and SEQ. ID. NO. 6).
  • FRDCA ligand 1
  • the fibrinogen-like domain of TIE ligand-3 is believed to begin on or around the amino acid sequence which is encoded by nucleotides beginning around position 929 as set forth in FIGS. 21A-21C (SEQ. ID. NO. 9 and SEQ. ID. NO. 10).
  • the fibrinogen-like domain comprises the TIE-2 receptor binding domain.
  • the monomeric forms of the fibrinogen-like domain do not, however, appear to bind the receptor.
  • ligandbodies which comprise the fibrinogen-like domain of the TIE-2 ligands coupled to the Fc domain of IgG (“fFc's”). These ligandbodies, which form dimers, efficiently bind the TIE-2 receptor. Accordingly, the present invention contemplates the production of modified TIE ligandbodies which may be used as targeting agents, in diagnostics or in therapeutic applications, such as targeting agents for tumors and/or associated vasculature wherein a TIE antagonist is indicated.
  • the invention herein further provides for the development of the ligand, a fragment or derivative thereof, or another molecule which is a receptor agonist or antagonist, as a therapeutic for the treatment of patients suffering from disorders involving cells, tissues or organs which express the TIE receptor.
  • Such molecules may be used in a method of treatment of the human or animal body, or in a method of diagnosis.
  • TIE-2 ligand has been identified in association with endothelial cells and, as demonstrated herein, blocking of TIE-2 ligand 1 appears to prevent vascularization
  • a modified TIE-2 ligand described herein may be useful for the induction of vascularization in diseases or disorders where such vascularization is indicated. Such diseases or disorders would include wound healing, ischaemia and diabetes.
  • the ligands may be tested in animal models and used therapeutically as described for other agents, such as vascular endothelial growth factor (VEGF), another endothelial cell-specific factor that is angiogenic.
  • VEGF vascular endothelial growth factor
  • Ferrara et al. U.S. Pat. No. 5,332,671 issued Jul. 26, 1994.
  • the Ferrara reference as well as other studies, describe in vitro and in vivo studies that may be used to demonstrate the effect of an angiogenic factor in enhancing blood flow to ischemic myocardium, enhancing wound healing, and in other therapeutic settings wherein neoangiogenesis is desired.
  • Sudo et al. European Patent Application 0 550 296 A2 published Jul. 7, 1993; Banai, et al. Circulation 89:2183-2189 (1994); Unger, et al. Am. J. Physiol. 266:H1588-H1-595 (1994); Lazarous, et al. Circulation 91:145-153 (1995)].
  • a modified TIE-2 ligand may be used alone or in combination with one or more additional pharmaceutically active compounds such as, for example, VEGF or basic fibroblast growth factor (bFGF), as well as cytokines, neurotrophins, etc.
  • additional pharmaceutically active compounds such as, for example, VEGF or basic fibroblast growth factor (bFGF), as well as cytokines, neurotrophins, etc.
  • TIE-2 ligands which bind but do not activate the receptor as described herein, receptorbodies as described herein in Examples 2 and 3, and TIE-2 ligand 2 as described in Example 9, would be useful to prevent or attenuate vascularization, thus preventing or attenuating, for example, tumor growth.
  • These agents may be used alone or in combination with other compositions, such as anti-VEGF antibodies, that have been shown to be useful in treating conditions in which the therapeutic intent is to block angiogenesis.
  • a modified TIE-2 ligand described herein may also be used in combination with agents, such as cytokine antagonists such as IL-6 antagonists, that are known to block inflammation.
  • TIE ligands are expressed in cells within, or closely associated with, tumors.
  • TIE-2 ligand 2 appears to be tightly associated with tumor endothelial cells. Accordingly, it and other TIE antagonists may also be useful in preventing or attenuating, for example, tumor growth.
  • TIE ligands or ligandbodies may be useful for the delivery of toxins to a receptor bearing cell.
  • other molecules such as growth factors, cytokines or nutrients, may be delivered to a TIE receptor bearing cell via TIE ligands or ligandbodies.
  • TIE ligands or ligandbodies such as modified TIE-2 ligand described herein may also be used as diagnostic reagents for TIE receptor, to detect the receptor in vivo or in vitro.
  • TIE receptor is associated with a disease state
  • TIE ligands or ligandbodies such as a modified TIE-2 ligand may be useful as diagnostic reagents for detecting the disease by, for example, tissue staining or whole body imaging.
  • Such reagents include radioisotopes, flurochromes, dyes, enzymes and biotin.
  • diagnostics or targeting agents may be prepared as described in Alitalo, et al. WO 95/26364 published Oct. 5, 1995 and Burrows, F. and P. Thorpe, PNAS (USA) 90:8996-9000 (1993) which is incorporated herein in its entirety.
  • the TIE ligands, a receptor activating modified TIE-2 ligand described herein are used as hematopoietic factors.
  • a variety of hematopoietic factors and their receptors are involved in the proliferation and/or differentiation and/or migration of the various cells types contained within blood. Because the TIE receptors are expressed in early hematopoietic cells, the TIE ligands are expected to play a comparable role in the proliferation or differentiation or migration of these cells.
  • TIE containing compositions may be prepared, assayed, examined in in vitro and in vivo biological systems and used therapeutically as described in any of the following: Sousa, U.S. Pat. No.
  • receptor activating modified TIE-2 ligand may be used to diagnose or treat conditions in which normal hematopoiesis is suppressed, including, but not limited to anemia, thrombocytopenia, leukopenia and granulocytopenia.
  • receptor activating modified TIE-2 ligand may be used to stimulate differentiation of blood cell precursors in situations where a patient has a disease, such as acquired immune deficiency syndrome (AIDS) which has caused a reduction in normal blood cell levels, or in clinical settings in which enhancement of hematopoietic populations is desired, such as in conjunction with bone marrow transplant, or in the treatment of aplasia or myelosuppression caused by radiation, chemical treatment or chemotherapy.
  • AIDS acquired immune deficiency syndrome
  • the receptor activating modified TIE-2 ligands of the present invention may be used alone, or in combination with another pharmaceutically active agent such as, for example, ctyokines, neurotrophins, interleukins, etc.
  • the ligands may be used in conjunction with any of a number of the above referenced factors which are known to induce stem cell or other hematopoietic precursor proliferation, or factors acting on later cells in the hematopoietic pathway, including, but not limited to, hemopoietic maturation factor, thrombopoietin, stem cell factor, erythropoietin, G-CSF, GM-CSF, etc.
  • TIE receptor antagonists are used to diagnose or treat patients in which the desired result is inhibition of a hematopoietic pathway, such as for the treatment of myeloproliferative or other proliferative disorders of blood forming organs such as thrombocythemias, polycythemias and leukemias.
  • treatment may comprise use of a therapeutically effective amount of the a modified TIE-2 ligand, TIE antibody, TIE receptorbody, a conjugate of a modified TIE-2 ligand, or a ligandbody or fFC as described herein.
  • the present invention also provides for pharmaceutical compositions comprising a modified TIE-2 ligand or ligandbodies described herein, peptide fragments thereof, or derivatives in a pharmacologically acceptable vehicle.
  • the modified TIE-2 ligand proteins, peptide fragments, or derivatives may be administered systemically or locally. Any appropriate mode of administration known in the art may be used, including, but not limited to, intravenous, intrathecal, intraarterial, intranasal, oral, subcutaneous, intraperitoneal, or by local injection or surgical implant. Sustained release formulations are also provided for.
  • the present invention also provides for an antibody which specifically binds such a therapeutic molecule.
  • the antibody may be monoclonal or polyclonal.
  • the invention also provides for a method of using such a monoclonal or polyclonal antibody to measure the amount of the therapeutic molecule in a sample taken from a patient for purposes of monitoring the course of therapy.
  • the invention further provides for a therapeutic composition
  • a therapeutic composition comprising a modified TIE-2 ligand or ligandbody and a cytotoxic agent conjugated thereto.
  • the cytotoxic agent may be a radioisotope or toxin.
  • the invention also provides for an antibody which specifically binds a modified TIE-2 ligand.
  • the antibody may be monoclonal or polyclonal.
  • the invention further provides for a method of purifying a modified TIE-2 ligand comprising:
  • the substrate may be any substance that specifically binds the modified TIE-2 ligand.
  • the substrate is selected from the group consisting of anti-modified TIE-2 ligand antibody, TIE receptor and TIE receptorbody.
  • the invention further provides for a receptorbody which specifically binds a modified TIE-2 ligand, as well as a therapeutic composition comprising the receptorbody in a pharmaceutically acceptable vehicle, and a method of blocking blood vessel growth in a human comprising administering an effective amount of the therapeutic composition.
  • the invention also provides for a therapeutic composition comprising a receptor activating modified TIE-2 ligand or ligandbody in a pharmaceutically acceptable vehicle, as well as a method of promoting neovascularization in a patient comprising administering to the patient an effective amount of the therapeutic composition.
  • the present invention provides for a method for identifying a cell which expresses TIE receptor which comprises contacting a cell with a detectably labeled modified TIE-2 ligand or ligandbody, under conditions permitting binding of the detectably labeled ligand to the TIE receptor and determining whether the detectably labeled ligand is bound to the TIE receptor, thereby identifying the cell as one which expresses TIE receptor.
  • the present invention also provides for a therapeutic composition comprising a modified TIE-2 ligand or ligandbody and a cytotoxic agent conjugated thereto.
  • the cytotoxic agent may be a radioisotope or toxin.
  • the invention also provides a method of detecting expression of a modified TIE-2 ligand by a cell which comprises obtaining mRNA from the cell, contacting the mRNA so obtained with a labeled nucleic acid molecule encoding a modified TIE-2 ligand, under hybridizing conditions, determining the presence of mRNA hybridized to the labeled molecule, and thereby detecting the expression of a modified TIE-2 ligand in the cell.
  • the invention further provides a method of detecting expression of a modified TIE-2 ligand in tissue sections which comprises contacting the tissue sections with a labeled nucleic acid molecule encoding a modified TIE-2 ligand, under hybridizing conditions, determining the presence of mRNA hybridized to the labelled molecule, and thereby detecting the expression of a modified TIE-2 ligand in tissue sections.
  • RNA analyses revealed moderate levels of tie-2 transcripts in the ABAE (Adult Bovine Arterial Endothelial) cell line, consistent with in situ hybridization results that demonstrated almost exclusive localization of tie-2 RNAs to vascular endothelial cells.
  • ABAE Adult Bovine Arterial Endothelial
  • TIE-2 ABAE cell lysates were harvested and subjected to immunoprecipitation, followed by Western blot analyses of immunoprecipitated proteins with TIE-2 specific and phosphotyrosine-specific antisera. Omission or inclusion of TIE-2 peptides as specific blocking molecules during TIE-2 immunoprecipitation allowed unambiguous identification of TIE-2 as a moderately detectable protein of ⁇ 150 kD whose steady-state phosphotyrosine levels diminish to near undetectable levels by prior serum-starvation of the cells.
  • ABAE cells Culture of ABAE cells and harvest of cell lysates was done as follows. Low-passage-number ABAE cells were plated as a monolayer at a density of 2 ⁇ 10 6 cells/150 mm plastic petri plate (Falcon) and cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% bovine calf serum (10% BCS), 2 mM L-glutamine (Q) and 1% each of penicillin and streptomycin (P-S) in an atmosphere of 5% CO 2 .
  • DMEM Dulbecco's modified Eagle's medium
  • BCS bovine calf serum
  • Q 2 mM L-glutamine
  • P-S penicillin and streptomycin
  • cells Prior to harvest of cell lysates, cells were serum-starved for 24 hours in DMEM/Q/P-S, followed by aspiration of the medium and rinsing of the plates with ice-cold phosphate buffered saline (PBS) supplemented with sodium orthovanadate, sodium fluoride and sodium benzamidine. Cells were lysed in a small volume of this rinse buffer that had been supplemented with 1% NP40 detergent and the protease inhibitors PMSF and aprotinin. Insoluble debris was removed from the cell lysates by centrifugation at 14,000 ⁇ G for 10 minutes, at 4° C.
  • PBS ice-cold phosphate buffered saline
  • TIE-2 receptor specific for TIE-2 receptor
  • blocking peptides added to ⁇ 20 ⁇ g/ml lysate.
  • Immunoprecipitated proteins were resolved by PAGE (7.5% Laemmli gel), and then electro-transferred to PVDF membrane and incubated either with various TIE-2- or phosphotyrosine-specific antisera.
  • TIE-2 protein was visualized by incubation of the membrane with HRP-linked secondary antisera followed by treatment with ECL reagent (Amersham).
  • TIE-2 receptorbody RB
  • the Fc portion of the TIE-2 RB was prepared as follows.
  • Appropriate DNA restriction fragments from a plasmid encoding the full-length TIE-2 receptor and from the human IgG1 Fc plasmid were ligated on either side of a short PCR-derived fragment that was designed so as to fuse, in-frame, the TIE-2 and human IgG1 Fc protein-coding sequences.
  • the resulting TIE-2 ectodomain-Fc fusion protein precisely substituted the IgG1 Fc in place of the region spanning the TIE-2 transmembrane and cytoplasmic domains.
  • An alternative method of preparing RBs is described in Goodwin, et. al. Cell 73:447-456 (1993).
  • Milligram quantities of TIE-2 RB were obtained by cloning the TIE-2 RB DNA fragment into the pVL1393 baculovirus vector and subsequently infecting the Spodoptera frugiperda SF-21AE insect cell line.
  • the cell line SF-9 ATCC Accession No. CRL-1711
  • the cell line BTI-TN-5b1-4 may be used.
  • DNA encoding the TIE-2 RB was cloned as an Eco RI-Notl fragment into the baculovirus transfer plasmid pVL1393.
  • Plasmid DNA purified by cesium chloride density gradient centrifugation was recombined into viral DNA by mixing 3 ⁇ g of plasmid DNA with 0.5 ⁇ g of Baculo-Gold DNA (Pharminigen), followed by introduction into liposomes using 30 ⁇ g Lipofectin (GIBCO-BRL).
  • DNA-liposome mixtures were added to SF-21AE cells (2 ⁇ 10 6 cells/60 mm dish) in TMN-FH medium (Modified Grace's Insect Cell Medium (GIBCO-BRL) for 5 hours at 27° C., followed by incubation at 27° C. for 5 days in TMN-FH medium supplemented with 5% fetal calf serum.
  • TMN-FH medium Modified Grace's Insect Cell Medium (GIBCO-BRL)
  • Tissue culture medium was harvested for plaque purification of recombinant viruses, which was carried out using methods previously described (O'Reilly, D. R., L. K. Miller, and V. A. Luckow, Baculovirus Expression Vectors—A Laboratory Manual . 1992, New York: W. H. Freeman) except that the agarose overlay contained 125 ⁇ g/mL X-gal (5-bromo-4-chloro-3-indolyl- ⁇ -D-galactopyranoside; GIBCO-BRL). After 5 days of incubation at 27° C., non-recombinant plaques were scored by positive chromogenic reaction to the X-gal substrate, and their positions marked.
  • Recombinant plaques were then visualized by addition of a second overlay containing 100 ⁇ g/mL MTT (3-[4,5-dimethylthiazol-2-yl]2,5,diphenyltetrazolium bromide; Sigma). Putative recombinant virus plaques were picked by plug aspiration, and purified by multiple rounds of plaque isolation to assure homogeneity. Virus stocks were generated by serial, low-multiplicity passage of plaque-purified virus. Low passage stocks of one virus clone (vTIE-2 receptorbody) were produced.
  • SF-21AE cells were cultured in serum free medium (SF-900 II, Gibco BRL) containing 1 ⁇ antibiotic/antimycotic solution (Gibco BRL) and 25 mg/L Gentamycin (Gibco BRL).
  • Pluronic F-68 was added as a surfactant to a final concentration of 1 g/L. Cultures (4L) were raised in a bioreactor (Artisan Cell Station System) for at least three days prior to infection.
  • Cells were grown at 27° C., with gassing to 50% dissolved oxygen, at a gas flow rate of 80 ml/min (aeration at a sparge ring). Agitation was by means of a marine impeller at a rate of 100 rpm. Cells were harvested in mid-logarithmic growth phase ( ⁇ 2 ⁇ 10 6 cells/mL), concentrated by centrifugation, and infected with 5 plaque forming units of vTIE-2 receptorbody per cell. Cells and inoculum were brought to 400 mL with fresh medium, and virus was adsorbed for 2 hours at 27° C. in a spinner flask. The culture was then resuspended in a final volume of 8L with fresh serum-free medium, and the cells incubated in the bioreactor using the previously described conditions.
  • Culture medium from vTIE-2 receptorbody-infected SF21AE cells were collected by centrifugation (500 ⁇ g, 10 minutes) at 72 hours post-infection. Cell supernatants were brought to pH 8 with NaOH. EDTA was added to a final concentration of 10 mM and the supernatant pH was readjusted to 8. Supernatants were filtered (0.45 ⁇ m, Millipore) and loaded on a protein A column (protein A sepharose 4 fast flow or HiTrap protein A, both from Pharmacia). The column was washed with PBS containing 0.5 M NaCl until the absorbance at 280 nm decreased to baseline. The column was washed in PBS and eluted with 0.5 M acetic acid. Column fractions were immediately neutralized by eluting into tubes containing 1 M Tris pH 9. The peak fractions containing the TIE-2 receptorbody were pooled and dialyzed versus PBS.
  • TIE-2 RB soluble TIE-2 receptorbody
  • CAM chorioallantoic membrane
  • Extra-embryonically-derived endothelial cells which provide the major source of endothelial cells in the embryo, originate from accretions of mesenchyme that are situated laterally around the embryo-proper, just underneath the CAM. As these mesenchyme cells mature, they give rise to a common progenitor of both the endothelial and hematopoietic cell lineages, termed the hemangioblast.
  • the hemangioblast gives rise to a mixed population of angioblasts (the endothelial cell progenitor) and hematoblasts (the pluripotential hematopoietic precursor).
  • angioblasts the endothelial cell progenitor
  • hematoblasts the pluripotential hematopoietic precursor.
  • Formation of rudiments of the circulatory system begins when endothelial cell progeny segregate to form a one-cell-thick vesicle that surrounds the primitive blood cells. Proliferation and migration of these cellular components eventually produces a vast network of blood-filled microvessels under the CAM that will ultimately invade the embryo to join with limited, intra-embryonically-derived vascular elements.
  • Newly fertilized chicken eggs obtained from Spafas, Inc. (Boston, Mass.) were incubated at 99.5° F., 55% relative humidity. At about 24 hrs. of development, the egg shell was wiped down with 70% ethanol and a dentist's drill was used to make a 1.5 cm. hole in the blunt apex of each egg. The shell membrane was removed to reveal an air space directly above the embryo. Small rectangular pieces of sterile Gelfoam (Upjohn) were cut with a scalpel and soaked in equal concentrations of either TIE-2- or EHK-1 receptorbody.
  • EHK-1 receptorbody was made as set forth in Example 2 using the EHK-1 extracellular domain instead of the TIE-2 extracellular domain (Maisonpierre et al., Oncogene 8:3277-3288 (1993).
  • Each Gelfoam piece absorbed approximately 6 ⁇ g of protein in 30 ⁇ l.
  • Sterile watchmakers forceps were used to make a small tear in the CAM at a position several millimeters lateral to the primitive embryo.
  • the majority of the piece of RB-soaked Gelfoam was inserted under the CAM and the egg shell was sealed over with a piece of adhesive tape.
  • the C2C12-ras 10 ⁇ CCM originated from a stably transfected line of C2C12 myoblasts that was oncogenically transformed by transfection with the T-24 mutant of H-ras by standard calcium phosphate-based methods.
  • An SV40 based neomycin-resistance expression plasmid was physically linked with the ras expression plasmid in order to permit selection of transfected clones.
  • Resulting G418-resistant ras-C2C12 cells were routinely maintained as a monolayer on plastic dishes in DMEM/glutamine/penicillin-streptomycin supplemented with 10% fetal calf serum (FCS).
  • FCS fetal calf serum
  • Serum-free C2C12-ras 10 ⁇ CCM was made by plating the cells at 60% confluence in a serum free defined media for 12 hours. [Zhan and Goldfarb, Mol. Cell. Biol. 6: 3541-3544 (1986)); Zhan, et al. Oncogene 1: 369-376 (1987)].
  • the medium was discarded and replaced with fresh DMEM/Q/P-S for 24 hours. This medium was harvested and cells were re-fed fresh DMEM/Q/P-S, which was also harvested after a further 24 hours.
  • TIE-2-binding activity could be neutralized by incubation of the medium with an excess of TIE-2 RB, but not by incubation with EHK-1 RB, prior to BlAcore analysis.
  • Binding activity of the 10 ⁇ CCM was measured using biosensor technology (BIAcore; Pharmacia Biosensor, Piscataway, N.J.) which monitors biomolecular interactions in real-time via surface plasmon resonance.
  • Purified TIE-2 RB was covalently coupled through primary amines to the carboxymethyl dextran layer of a CM5 research grade sensor chip (Pharmacia Biosensor; Piscataway, N.J.).
  • the sensor chip surface was activated using a mixture of N-hydroxysuccinimide (NHS) and N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide (EDC), followed by immobilization of TIE-2 RB (25 ⁇ g/mL, pH 4.5) and deactivation of unreacted sites with 1.0 M ethanolamine (pH 8.5).
  • a negative control surface of the EHK-1 receptorbody was prepared in a similar manner.
  • the running buffer used in the system was HBS (10 mM Hepes, 3.4 mM EDTA, 150 mM NaCl, 0.005% P20 surfactant, pH 7.4).
  • the 10 ⁇ CCM samples were centrifuged for 15 min at 4° C. and further clarified using a sterile, low protein-binding 0.45 ⁇ m filter (Millipore; Bedford, Mass.). Dextran (2 mg/ml) and P20 surfactant (0.005%) were added to each CCM sample. Aliquots of 40 ⁇ L were injected across the immobilized surface (either TIE-2 or EHK-1) at a flow rate of 5 ⁇ l/min and the receptor binding was monitored for 8 min.
  • the binding activity (resonance units, RU) was measured as the difference between a baseline value determined 30 s prior to the sample injection and a measurement taken at 30 s post-injection. Regeneration of the surface was accomplished with one 12- ⁇ L pulse of 3 M MgCl 2 .
  • the instrument noise level is 20 RU; therefore, any binding activity with a signal above 20 RU may be interpreted as a real interaction with the receptor.
  • the binding activities were in the range 60-90 RU for the TIE-2 RB immobilized surface.
  • the measured activities were less than 35 RU.
  • Specific binding to the TIE-2 receptorbody was evaluated by incubating the samples with an excess of either soluble TIE-2 or EHK-1 RB prior to assaying the binding activity.
  • C2C12-ras 10 ⁇ CCM was examined for its ability to induce tyrosine phosphorylation of TIE-2 in ABAE cells.
  • Serum-starved ABAE cells were briefly incubated with C2C12-ras CCM, lysed and subjected to immunoprecipitation and Western analyses as described above.
  • Stimulation of serum-starved ABAE cells with serum-free C2C12-ras 10 ⁇ CCM was done as follows. The medium of ABAE cells starved as described above was removed and replaced with either defined medium or 10 ⁇ CCM that had been pre-warmed to 37° C. After 10 minutes, the media were removed and the cells were twice rinsed on ice with an excess of chilled PBS supplemented with orthovanadate/NaF/benzamidine. Cell lysis and TIE-2-specific immunoprecipitation was done as described above.
  • ABAE cells incubated for 10 minutes with defined medium showed no induction of TIE-2 tyrosine phosphorylation, whereas incubation with C2C12-ras CCM stimulated at least a 100 ⁇ increase in TIE-2 phosphorylation. This activity was almost totally depleted by pre-incubation of the C2C12-ras 10 ⁇ CCM for 90 minutes at room temperature with 13 ⁇ g of TIE-2 RB coupled to protein G-Sepharose beads. Medium incubated with protein G Sepharose alone was not depleted of this phosphorylating activity.
  • COS-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 1% each of penicillin and streptomycin (P/S) and 2 mM glutamine in an atmosphere of 5% CO 2 .
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • P/S penicillin and streptomycin
  • 2 mM glutamine fetal bovine serum
  • the mouse myoblast C2C12 ras cell line was cultured in Eagle's minimal essential medium (EMEM) with 10% FBS, (P/S) and 2 mM glutamine.
  • Full length mouse TIE-2 ligand cDNA clones were obtained by screening a C2C12 ras cDNA library in the pJFE14 vector expressed in COS cells.
  • This vector is a modified version of the vector pSR ⁇ (Takebe, et al. 1988, Mol. Cell. Bio
  • COS-7 cells were transiently transfected with either the pJFE14 library or control vector by the DEAE-dextran transfection protocol. Briefly, COS-7 cells were plated at a density of 1.0 ⁇ 10 6 cells/100 mm plate 24 hours prior to transfection. For transfection, the cells were cultured in serum-free DMEM containing 400 ⁇ g/ml of DEAE-dextran, 1 ⁇ M chloroquine, and 2 mM glutamine, and 1 ⁇ g of the appropriate DNA for 3-4 hours at 37° C. in an atmosphere of 5% CO 2 . The transfection media was aspirated and replaced with PBS with 10% DMSO for 2-3 min. Following this DMSO “shock”, the COS-7 cells were placed into DMEM with 10% FBS, 1% each of penicillin and streptomycin, and 2 mM glutamine for 48 hours.
  • TIE-2 ligand Because the TIE-2 ligand is secreted it was necessary to permeabilize the cells to detect binding of the receptorbody probe to the ligand. Two days after transfection the cells were rinsed with PBS and then incubated with PBS containing 1.8% formaldehyde for 15-30 min. at room temperature. Cells were then washed with PBS and incubated for 15 min. with PBS containing 0.1% Triton X-100 and 10% Bovine Calf Serum to permeabilize the cells and block non-specific binding sites.
  • TIE-2 receptorbody which consisted of the extracellular domain of TIE-2 fused to the IgG1 constant region.
  • This receptorbody was prepared as set forth in Example 2.
  • a 100 mm dish of transfected, fixed and permeabilized COS cells was probed by incubating them for 30 min with TIE-2 RB.
  • the cells were then washed twice with PBS and incubated for an additional 30 min with PBS/10% Bovine Calf Serum/anti-human IgG-alkaline phosphatase conjugate. After three PBS washes, cells were incubated in alkaline-phosphatase substrate for 30-60 min. The dish was then inspected microscopically for the presence of stained cells.
  • TIE-2 ligand expression was obtained by phosphorylation of the TIE-2 receptor using the method set forth in Example 5.
  • a plasmid clone encoding the TIE-2 ligand was deposited with the ATCC on Oct. 7, 1994 and designated as “pJFE14 encoding TIE-2 ligand” under ATCC Accession No. 75910.
  • a human fetal lung cDNA library in lambda gt-10 was obtained from Clontech Laboratories, Inc. (Palo Alto, Calif.). Plaques were plated at a density of 1.25 ⁇ 10 6 /20 ⁇ 20 cm plate, and replica filters taken following standard procedures (Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., page 8.46, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).
  • Isolation of human tie-2 ligand clones was carried out as follows. A 2.2 kb XhoI fragment from the deposited tie-2 ligand clone (ATCC NO. 75910—see Example 6 above) was labeled by random priming to a specific activity of approximately 5 ⁇ 10 8 cpm/ng. Hybridization was carried out at 65° C. in hybridization solution containing 0.5 mg/ml salmon sperm DNA. The filters were washed at 65° C. in 2 ⁇ SSC, 0.1% SDS and exposed to Kodak XAR-5 film overnight at ⁇ 70° C. Positive phage were plaque purified.
  • Phage DNA was digested with EcoRI to release the cloned cDNA fragment for subsequent subcloning.
  • a lambda phage vector containing human tie-2 ligand DNA was deposited with the ATCC on Oct. 26, 1994 under the designation ⁇ gt10 encoding htie-2 ligand 1 (ATCC Accession No. 75928).
  • Phage DNA may be subjected directly to DNA sequence analysis by the dideoxy chain termination method (Sanger, et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74: 5463-5467).
  • Subcloning of the human tie-2 ligand DNA into a mammalian expression vector may be accomplished as follows.
  • the clone ⁇ gt10 encoding htie-2 ligand 1 contains an EcoRI site located 490 base pairs downstream from the start of the coding sequence for the human TIE-2 ligand.
  • the coding region may be excised using unique restriction sites upstream and downstream of the initiator and stop codons respectively. For example, an Spel site, located 70 bp 5′ to the initiator codon, and a Bpu1102i (also known as BIpi) site, located 265 bp 3′ to the stop codon, may be used to excise the complete coding region. This may then be suboloned into the pJFE14 cloning vector, using the Xbal (compatible to the Spel overhang) and the Pstl sites (the PstI and Bpu1102i sites are both made blunt ended).
  • the coding region from the clone ⁇ gt10 encoding htie-2 ligand 1 was sequenced using the ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, Calif.).
  • the nucleotide and deduced amino acid sequence of human TIE-2 ligand from the clone ⁇ gt10 encoding htie-2 ligand 1 is shown in FIGS. 4A-4D (SEQ. ID. NO. 1 and SEQ. ID. NO. 2).
  • full length human tie-2 ligand cDNA clones were obtained by screening a human glioblastoma T98G cDNA library in the pJFE14 vector.
  • Clones encoding human TIE-2 ligand were identified by DNA hybridization using a 2.2 kb XhoI fragment from the deposited tie-2 ligand clone (ATCC NO. 75910) as a probe (see Example 6 above).
  • the coding region was sequenced using the ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, Calif.). This sequence was nearly identical to that of clone ⁇ gt10 encoding htie-2 ligand 1. As shown in FIGS.
  • the clone ⁇ gt10 encoding htie-2 ligand 1 contains an additional glycine residue which is encoded by nucleotides 1114-1116.
  • the coding sequence of the T98G clone does not contain this glycine residue but otherwise is identical to the coding sequence of the clone ⁇ gt10 encoding htie-2 ligand 1.
  • FIGS. 5A-5D (SEQ. ID. NO. 1 and SEQ. ID. NO. 4) sets forth the nucleotide and deduced amino acid sequence of human TIE-2 ligand from the T98G clone.
  • a human fetal lung cDNA library in lambda gt-10 was obtained from Clontech Laboratories, Inc. (Palo Alto, Calif.). Plaques were plated at a density of 1.25 ⁇ 10 6 /20 ⁇ 20 cm plate, and replica filters taken following standard procedures (Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., page 8.46, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). Duplicate filters were screened at low stringency (2 ⁇ SSC, 55° C.) with probes made to the human TIE-2 ligand 1 sequence.
  • the duplicate filters was probed with a 5′ probe, encoding amino acids 25-265 of human TIE-2 ligand 1 as set forth in FIGS. 4A-4D (SEQ. ID. NO. 1 and SEQ. ID. NO. 2).
  • the second duplicate filter was probed with a 3′ probe, encoding amino acids 282-498 of human TIE-2 ligand 1 sequence (see FIGS. 4A-4D (SEQ. ID. NO. 1 and SEQ. ID. NO. 2)). Both probes were hybridized at 55° C. in hybridization solution containing 0.5 mg/ml salmon sperm DNA. Filters were washed in 2 ⁇ SSC at 55° C. and exposed overnight to X-ray film.
  • duplicate filters were also hybridized at normal stringency (2 ⁇ SSC, 65° C.) to the full length coding probe of mouse TIE-2 ligand 1 (F3-15, Xhol insert).
  • Three positive clones were picked that fulfilled the following criteria: i. hybridization had not been seen to the full length (mouse) probe at normal stringency, and ii. hybridization was seen at low stringency to both 5′ and 3′ probes.
  • EcoRI digestion of phage DNA obtained from these clones indicated two independent clones with insert sizes of approximately 2.2 kb and approximately 1.8 kb.
  • the 2.2 kb EcoRI insert was subcloned into the EcoRI sites of both pBluescript KS (Stratagene) and a mammalian expression vector suitable for use in COS cells. Two orientations were identified for the mammalian expression vector.
  • the 2.2 kb insert in pBluescript KS was deposited with the ATCC on Dec. 9, 1994 and designated as pBluescript KS encoding human TIE 2 ligand 2.
  • the start site of the TIE-2 ligand 2 coding sequence is approximately 355 base pairs downstream of the pBluescript EcoRI site.
  • COS-7 cells were transiently transfected with either the expression vector or control vector by the DEAE-dextran transfection protocol. Briefly, COS-7 cells were plated at a density of 1.0 ⁇ 10 6 cells/100 mm plate 24 hours prior to transfection. For transfection, the cells were cultured in serum-free DMEM containing 400 ⁇ g/ml of DEAE-dextran, 1 ⁇ M chloroquine, and 2 mM glutamine, and 1 ⁇ g of the appropriate DNA for 3-4 hours at 37° C. in an atmosphere of 5% CO 2 . The transfection media was aspirated and replaced with phosphate-buffered saline with 10% DMSO for 2-3 min. Following this DMSO “shock”, the COS-7 cells were placed into DMEM with 10% FBS, 1% each of penicillin and streptomycin, and 2 mM glutamine for 48 hours.
  • Transfected COS-7 cells were plated at a density of 1.0 ⁇ 10 6 cells/100 mm plate. The cells were rinsed with PBS and then incubated with PBS containing 1.8% formaldehyde for 15-30 min. at room temperature. Cells were then washed with PBS and incubated for 15 min. with PBS containing 0.1% Triton X-100 and 10% Bovine Calf Serum to permeabilize the cells and block non-specific binding sites.
  • TIE-2 receptorbody which consisted of the extracellular domain of TIE-2 fused to the IgG1 constant region.
  • This receptorbody was prepared as set forth in Example 2.
  • Transfected COS cells were probed by incubating them for 30 min with TIE-2 receptorbody.
  • the cells were then washed twice with PBS, fixed with methanol, and then incubated for an additional 30 min with PBS/10% Bovine Calf Serum/anti-human IgG-alkaline phosphatase conjugate. After three PBS washes, cells were incubated in alkaline-phosphatase substrate for 30-60 min. The dish was then inspected microscopically for the presence of stained cells. Cells expressing one orientation of the clone, but not the other orientation, were seen to bind the TIE-2 receptorbody.
  • the coding region from the clone pBluescript KS encoding human TIE-2 ligand 2 was sequenced using the ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, Calif.).
  • the nucleotide and deduced amino acid sequence of human TIE-2 ligand from the clone pBluescript KS encoding human TIE-2 ligand 2 is shown in FIG. 6 (SEQ. ID. NO. 5 and SEQ. ID. NO. 6).
  • TIE-2 LIGAND 2 IS A RECEPTOR ANTAGONIST
  • TIE-2 ligand 2 TL2
  • TIE-2 ligand 1 TL1
  • Lipofectamine reagent (GIBCO-BRL, Inc.) and recommended protocols were used to transfect COS-7 cells with either the pJFE14 expression vector alone, pJFE14 vector containing the human TIE-2 ligand 1 cDNA, or with a pMT21 expression vector (Kaufman, R. J., 1985, Proc. Natl. Acad. Sci. USA 82: 689-693) containing the human TIE-2 ligand 2 cDNA.
  • COS media containing secreted ligands were harvested after three days and concentrated 20-fold by diafiltration (DIAFLO ultrafiltration membranes, Amicon, Inc.). The quantity of active TIE-2 ligand 1 and TIE-2 ligand 2 present in these media was determined and expressed as the amount (in resonance units, R.U.) of TIE-2 receptor specific binding activity measured by a BIAcore binding assay.
  • RNA analyses revealed significant levels of TIE-2 transcripts in HAEC (Human Aortic Endothelial Cell) human primary endothelial cells (Clonetics, Inc.). Therefore, these cells were used to examine whether TIE-2 receptor is tyrosine-phosphorylated when exposed to COS media containing the TIE-2 ligands.
  • HAEC cells were maintained in a complete endothelial cell growth medium (Clonetics, Inc.) that contained 5% fetal bovine serum, soluble bovine brain extract, 10 ng/ml human EGF, 1 mg/ml hydrocortisone, 50 mg/ml gentamicin and 50 ng/ml amphotericin-B.
  • TIE-2 receptor protein was recovered by immunoprecipitation of the lysates with TIE-2 peptide antiserum, followed by Western blotting with antiphosphotyrosine antiserum, exactly as described in example 1. The results are shown in FIG.
  • TIE-2-R Phosphotyrosine levels on the TIE-2 receptor
  • MOCK is conditioned media from COS transfected with JFE14 empty vector.
  • TIE-2 receptor specific binding activities were demonstrated by using a BIAcore to assay the TIE-2 receptor specific binding activities in transfected COS media and by immunostaining of TL1- and TL2-expressing COS cells with TIE-2 receptorbodies.
  • TL2 did not activate the TIE-2 receptor, applicants set out to determine whether TL2 might be capable of serving as an antagonist of TL1 activity.
  • HAEC phosphorylation assays were performed in which cells were first incubated with an “excess” of TL2, followed by addition of dilute TL1. It was reasoned that prior occupancy of TIE-2 receptor due to high levels of TL2 might prevent subsequent stimulation of the receptor following exposure to TL1 present at a limiting concentration.
  • HAEC cells were serum-starved as described above and then incubated for 3 min., at 37° C. with 1-2 ml. of 20 ⁇ COS/JFE14-TL2 conditioned medium. Control plates were treated with 20 ⁇ COS/JFE14-only medium (MOCK). The plates were removed from the incubator and various dilutions of COS/JFE14-TL1 medium were then added, followed by further incubation of the plates for 5-7 min. at 37° C. Cells were subsequently rinsed, lysed and TIE-2-specific tyrosine phosphorylation in the lysates was examined by receptor immunoprecipitation and Western blotting, as described above.
  • MOCK 20 ⁇ COS/JFE14-only medium
  • TL1 dilutions were made using 20 ⁇ COS/JFE14-TL1 medium diluted to 2 ⁇ , 0.5 ⁇ , 0.1 ⁇ , or 0.02 ⁇ by addition of 20 ⁇ COS/JFE14-alone medium.
  • An assay of the initial 20 ⁇ TL1 and 20 ⁇ TL2 COS media using BIAcore biosensor technology indicated that they contained similar amounts of TIE-2-specific binding activities, i.e., 445 R.U. and 511 R.U. for TL1 and TL2, respectively.
  • the results of the antiphosphotyrosine Western blot, shown in FIG. 8, indicate that when compared to prior treatment of HAEC cells with MOCK medium (lane 1), prior treatment of HAEC cells with excess TIE-2 ligand 2 (lane. 2) antagonizes the subsequent ability of dilute TIE-2 ligand 1 to activate the TIE-2 receptor (TIE-2-R).
  • TL2 The ability of TL2 to competitively inhibit TL1 activation of the TIE-2-R was further demonstrated using the human cell hybrid line, EA.hy926 (see Example 21 for detailed description of this cell line and its maintenance).
  • EA.hy926 the human cell hybrid line
  • Experiments were performed in which unconcentrated COS cell media containing TL1 were mixed at varying dilutions with either MOCK- or TL2-conditioned media and placed on serum-starved EA.hy926 cell monolayers for 5 minutes at 37° C. The media were then removed, the cells were harvested by lysis and TIE-2-specific tyrosine phosphorylation was examined by Western blots, as described above.
  • FIG. 9 shows an experiment which contains three groups of treatments, as viewed from left to right.
  • TL1 When the amount TL1 was held steady and the amount of TL2 (or MOCK) was decreased, however (shown in the three pairs of lanes at the right), a point was reached at which the TL2 in the sample was too dilute to effectively inhibit TL1 activity.
  • the relative amount of each ligand present in these conditioned COS media could be estimated from their binding units as measured by the BIAcore assay and from Western blots of the COS media with ligand-specific antibodies. Consequently, we can infer that only a few-fold molar excess of TL2 is required to effectively block the activity of TL1 in vitro. This is significant because we have observed distinct examples in vivo (see Example 17 and FIG. 16) where TL2 mRNAs achieve considerable abundance relative to those of TL1. Thus, TL2 may be serving an important physiological role in effectively blocking signaling by the TIE-2-R at these sites.
  • TL2 is unable to stimulate endogenously expressed TIE-2-R on endothelial cells. Furthermore, at a few fold molar excess TL2 can block TL1 stimulation of the TIE-2 receptor, indicating that TL2 is a naturally occurring TIE-2 receptor antagonist.
  • Binding activity of 10 ⁇ CCM from the cell lines C2C12-ras, Rat2 ras, SHEP, and T98G, or COS cell supernatants after transfection with either human TIE-2 ligand 1 (hTL1) or human TIE-2 ligand 2 (hTL2) was measured using biosensor technology (BIAcore; Pharmacia Biosensor, Piscataway, N.J.) which monitors biomolecular interactions in real-time via surface plasmon resonance (SPR).
  • Purified rat or human TIE-2 RB was covalently coupled through primary amines to the carboxymethyl dextran layer of a CM5 research grade sensor chip (Pharmacia Biosensor; Piscataway, N.J.).
  • the sensor chip surface was activated using a mixture of N-hydroxysuccinimide (NHS) and N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide (EDC), followed by immobilization of TIE-2 RB (25 ⁇ g/mL, pH 4.5) and deactivation of unreacted sites with 1.0 M ethanolamine (pH 8.5).
  • NHS N-hydroxysuccinimide
  • EDC N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide
  • TIE-2 RB 25 ⁇ g/mL, pH 4.5
  • deactivation of unreacted sites with 1.0 M ethanolamine (pH 8.5).
  • 9000-10000 RU of each receptorbody was coupled to the sensor chip.
  • the running buffer used in the system was HBS (10 mM Hepes, 150 mM NaCl, 0.005% P20 surfactant, pH 7.4).
  • the samples were centrifuged for 15 min at 4° C. and further clarified using a sterile, low protein-binding 0.45 ⁇ m filter (Millipore; Bedford, Mass.). Dextran (2 mg/ml) and P20 surfactant (0.005%) were added to each sample. Aliquots of 40 ⁇ L were injected across the immobilized surface (either rat or human TIE-2) at a flow rate of 5 ⁇ L/min and the receptor binding was monitored for 8 min.
  • the binding activity (resonance units, RU) was measured as the difference between a baseline value determined 30 s prior to the sample injection and a measurement taken at 30 s post-injection. Regeneration of the surface was accomplished with one 15- ⁇ L pulse of 3 M MgCl 2 .
  • the CCM samples (C2C12-ras, Rat2-ras, SHEP, T98G) were tested on the rat TIE-2 RB immobilized surface, while the recombinant hTL1 and hTL2 were tested on the human TIE-2 RB immobilized surface.
  • specific binding to the TIE-2 receptorbody was evaluated by incubating the samples with 25 ⁇ g/ml of either soluble TIE-2 (rat or human) RB or trkB RB prior to assaying the binding activity.
  • the addition of soluble trkB RB causes a slight decrease in the TIE-2 binding activity
  • the addition of soluble TIE-2 RB significantly reduces the binding activity as compared to that measured in the absence of TIE-2 RB.
  • TIE-2 RB SPECIFICALLY BLOCKS ACTIVATION OF THE TIE-2 RECEPTOR BY TIE-2 LIGAND 1
  • TIE-2 ligand 1 TIE-2 ligand 1
  • Conditioned COS media were generated from COS-7 cells transfected with either the pJFE14 expression vector alone (MOCK), or pJFE14 vector containing the human TIE-2 ligand 1 cDNA (TL1) and harvested as described in Example 9 hereinabove, with the exception that the media were sterile filtered but not concentrated.
  • the quantity of TL1 was determined and expressed as the amount (in resonance units, R.U.) of TIE-2 receptor-specific binding activity measured by BIAcore binding assay.
  • RNA analyses revealed significant levels of tie-2 transcripts in HUVEC (Human Umbilical Vein Endothelial Cell) human primary endothelial cells (Clonetics, Inc.). Therefore, these cells were used to examine whether TIE-2 receptor can be tyrosine-phosphorylated when exposed in the presence of TIE-2- or TrkB-RBs to COS media containing TL1.
  • HUVEC cells were maintained at 37° C., 5% CO 2 in a complete endothelial cell growth medium (Clonetics, Inc.) that contained 5% fetal bovine serum, soluble bovine brain extract with 10 ⁇ g/ml heparin, 10 ng/ml human EGF, 1 ug/ml hydrocortisone, 50 ⁇ g/ml gentamicin and 50 ng/ml amphotericin-B. Assessment of whether TL1 could activate TIE-2 receptor in the HUVEC cells was done as follows.
  • Confluent dishes of HUVEC cells were serum-starved for two-to-four hours in low-glucose Dulbecco's MEM at 37° C., 5% CO 2 , followed by 10 minute incubation in starvation medium that included 0.1 mM sodium orthovanadate, a potent inhibitor of phosphotyrosine phosphatases. Meanwhile, conditioned COS media were preincubated 30 min. at room temperature with either TIE-2- or TrkB-RB added to 50 ⁇ g/ml. The starvation medium was then removed from the HUVEC dishes and incubated with the RB-containing COS media for 7 minutes at 37° C.
  • TIE-2 receptor protein was recovered by immunoprecipitation with TIE-2 peptide antiserum, followed by Western blotting with an anti-phosphotyrosine antibody, as described in Example 1.
  • FIG. 12 Phosphotyrosine levels on the TIE-2 receptor were induced by treatment of HUVEC cells with TIE-2 ligand 1 (TL1) relative to that seen with control medium (MOCK) and this induction is specifically blocked by prior incubation with TIE-2-RB (TIE-2-Fc) but not by incubation with TrkB-RB (TrkB-Fc).
  • TIE-2 ligand 1 TIE-2 ligand 1
  • TrkB-RB TrkB-RB
  • TIE-2 ligand 1 TL1
  • TIE-2 ligand 2 TL2
  • TIE-2 ligandbodies TIE-2 ligandbodies
  • Appropriate DNA restriction fragments from a plasmid encoding full-length TL1 or TL2 and from the human IgG1 Fc plasmid were ligated on either side of a short PCR-derived fragment that was designed so as to fuse, in-frame, TL1 or TL2 with human IgG1 Fc protein-coding sequences.
  • Milligram quantities of TL2-Fc were obtained by cloning the TL2-Fc DNA fragment into the pVL1393 baculovirus vector and subsequently infecting the Spodoptera frugiperda SF-21AE insect cell line.
  • the cell line SF-9 ATCC Accession No. CRL-1711
  • the cell line BTI-TN-5b1-4 may be used.
  • DNA encoding the TL2-Fc was cloned as an Eco RI-NotI fragment into the baculovirus transfer plasmid pVL1393.
  • Plasmid DNA was recombined into viral DNA by mixing 3 ⁇ g of plasmid DNA with 0.5 ⁇ g of Baculo-Gold DNA (Pharminigen), followed by introduction into liposomes using 30 ⁇ g Lipofectin (GIBCO-BRL). DNA-liposome mixtures were added to SF-21AE cells (2 ⁇ 106 cells/60 mm dish) in TMN-FH medium (Modified Grace's Insect Cell Medium (GIBCO-BRL) for 5 hours at 27° C., followed by incubation at 27° C. for 5 days in TMN-FH medium supplemented with 5% fetal calf serum.
  • TMN-FH medium Modified Grace's Insect Cell Medium (GIBCO-BRL)
  • Tissue culture medium was harvested for plaque purification of recombinant viruses, which was carried out using methods previously described (O'Reilly, D. R., L. K. Miller, and V. A. Luckow, Baculovirus Expression Vectors—A Laboratory Manual. 1992, New York: W. H. Freeman) except that the agarose overlay contained 125 mg/mL X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside; GIBCO-BRL). After 5 days of incubation at 27° C., non-recombinant plaques were scored by positive chromogenic reaction to the X-gal substrate, and their positions marked.
  • Recombinant plaques were then visualized by addition of a second overlay containing 100 mg/mL MTT (3-[4,5-dimethylthiazol-2-yl]2,5,diphenyltetrazolium bromide; Sigma). Putative recombinant virus plaques were picked by plug aspiration, and purified by multiple rounds of plaque isolation to assure homogeneity. Virus stocks were generated by serial, low-multiplicity passage of plaque-purified virus. Low passage stocks of one virus clone (vTL2-Fc Clone #7) were produced.
  • SF-21AE cells were cultured in serum-free medium (SF-900 II, Gibco BRL) containing 1 ⁇ antibiotic/antimycotic solution (Gibco BRL) and 25 mg/L Gentamycin (Gibco BRL).
  • Pluronic F-68 was added as a surfactant to a final concentration of 1 g/L.
  • Cultures (4L) were raised in a bioreactor (Artisan Cell Station System) for at least three days prior to infection. Cells were grown at 27° C., with gassing to 50% dissolved oxygen, at a gas flow rate of 80 mL/min (aeration at a sparge ring). Agitation was by means of a marine impeller at a rate of 100 rpm.
  • Cells were harvested in mid-logarithmic growth phase ( ⁇ 2 ⁇ 10 6 cells/mL), concentrated by centrifugation, and infected with 5 plaque forming units of vTL2-Fc per cell. Cells and inoculum were brought to 400 mL with fresh medium, and virus was adsorbed for 2 hours at 27° C. in a spinner flask. The culture was then resuspended in a final volume of 8L with fresh serum-free medium, and the cells incubated in the bioreactor using the previously described conditions.
  • Culture medium from vTL2-Fc-infected SF21AE cells were collected by centrifugation (500 ⁇ g, 10 minutes) at 72 hours post-infection. Cell supernatants were brought to pH 8 with NaOH. EDTA was added to a final concentration of 10 mM and the supernatant pH was readjusted to 8. Supernatants were filtered (0.45 ⁇ m, Millipore) and loaded on a protein A column (protein A sepharose 4 fast flow or HiTrap protein A, both from Pharmacia). The column was washed with PBS containing 0.5 M NaCl until the absorbance at 280 nm decreased to baseline. The column was washed in PBS and eluted with 0.5 M acetic acid. Column fractions were immediately neutralized by eluting into tubes containing 1 M Tris pH 9. The peak fractions containing the TL2-Fc were pooled and dialyzed versus PBS.
  • TIE-1, TIE-2, TL1, and TL2 cDNA probes were all up-regulated in the tumor vasculature.
  • Ligand expression appeared to be localized to either the vascular endothelial cells (TL2) or very near the vascular endothelial cells in the mesenchyme (TL1).
  • VEGF has been shown to be dramatically up-regulated in this tumor tissue. Brown, et al. Am. J. Pathol. 143:1255-1262 (1993).
  • In situ hybridization experiments were performed on cross-sectional tissue slices obtained from a rat cutaneous wound model using TIE-1, TIE-2, TL1, and TL2 cDNA probes.
  • the wound healing model involves pressing a small cork bore against the skin of a rat and removing a small, cylindrical plug of skin. As healing begins at the base of the wound, a vertical slice of tissue is taken and used for in situ hybridization.
  • TL1 and TL2 appeared to be slightly up-regulated by four days post-injury.
  • VEGF expression which may precede TL1 and TL2 expression, is dramatically up-regulated.
  • RT-PCR Reverse transcription-PCR
  • TIE-2 ligand 1 RNA is enriched in the stromal region, but is absent in c-kit + TER119 hematopoietic precursor cells.
  • TIE-2 ligand 2 TL2 RNA is enriched in the stromal cells, but absent in the hematopoietic precursor cells (FIG. 13 ).
  • TL2 is enriched in the stromal cells (FIG. 14 ).
  • TIE-2/TIE ligand system appears to play an important role in endothelial cell biology, it has not been shown to play a significant, active role in the early to intermediate stages of vascularization (e.g. angioblast or endothelial cell proliferation and migration, tubule formation, and other early stage events in vascular modeling).
  • vascularization e.g. angioblast or endothelial cell proliferation and migration, tubule formation, and other early stage events in vascular modeling.
  • the temporally late pattern of expression of TIE-2 and TL1 in the course of vascularization suggests that this system plays a distinct role in the latter stages vascular development, including the structural and functional differentiation and stabilization of new blood vessels.
  • the pattern of expression of TIE-2/TL1 also is consistent with a continuing role in the maintenance of the structural integrity and/or physiological characteristics of an established vasculature.
  • TIE Ligand 2 (TL2) appears to be a competitive inhibitor of TL1.
  • the spatiotemporal characteristics of TL2 expression suggest that this single inhibitory molecule may play multiple, context-dependent roles essential to appropriate vascular development or remodeling (e.g. de-stabilization/de-differentiation of mature endothelial cells allowing the formation of new vessels from existing vasculature, inhibition of inappropriate blood vessel formation, and regression/involution of mature blood vessels).
  • FIG. 15 is a schematic representation of the hypothesized role of the TIE-2/TIE ligands in angiogenesis.
  • TL1 is represented by (•)
  • TL2 is represented by (*)
  • TIE-2 is represented by (T)
  • VEGF is represented by ([])
  • flk-1 (a VEGF receptor) is represented by (Y).
  • TL1 plays a role in neovascularization which temporally follows that of VEGF.
  • the pattern of TL2 expression is also consistent with an antagonism of the action of TL1, and a specific role in vascular regression.
  • expression of relevant mRNAs can be examined following experimental induction of follicular and luteal development so that their temporal relation to various aspects of neovascularization/vascular regression can be more clearly defined (e.g. in conjunction with endothelial cell staining, vascular fills).
  • FIG. 16 contains photographs of in situ hybridization slides showing the temporal expression pattern of TIE-2, TL1, TL2, and VEGF during the ovarian cycle [Column 1: Early pre-ovulatory follicle; Column 2: pre-ovulatory follicle; Column 3: early corpus luteum; and Column 4: atretic follicle; Row A:bright field; Row B:VEGF; Row C: TL2; Row D: TL1 and Row E: TIE-2 receptor].
  • VEGF, TL1 and TL2 are expressed in a temporally and spatially coordinate fashion with respect to the development and regression of vasculature in the ovary, specifically with respect to the establishment of the vascular system which is generated in the course of the conversion of an ovarian follicle to a corpus luteum (CL).
  • VEGF expression increases in the follicular granule layer prior to its vascularization during the process of luteinization.
  • highest levels of VEGF expression are apparent in the center of the developing CL in the vicinity of luteinizing cells which are not yet vascularized.
  • VEGF levels remain moderately high and are diffusely distributed in the developed CL.
  • noticeably enhanced expression of TIE-2 ligand 1 occurs only late in process of CL formation, after a primary vascular plexus has been established. Later, TL1 expression is apparent throughout the CL at which time the definitive capillary network of the CL has been established.
  • TL2 exhibits a more complex pattern of expression than either VEGF or TL1.
  • TL2 is expressed at highest levels at the front of the developing capillary plexus-between the central avascular region of the CL where VEGF expression is highest, and the most peripheral portion of the CL where TL1 expression is dominant and where the luteinization process is complete and the vascular system is most mature.
  • TL2 also appears to be expressed at high levels in the follicular layer of large follicles which are undergoing atresia. While TL1 is also apparent in atretic follicles, VEGF is not expressed.
  • TL2 is present both in areas of active expansion of a newly forming vascular network (during CL formation), and in regions which fail to establish a new vasculature and vascular regression is in progress (atretic follicles). This suggests a more dynamic and complex role for TL2, possibly involving destabilization of existing vasculature (necessary for regression) or developing vasculature (necessary for the dynamic modeling of newly forming vessels).
  • TIE-2 receptorbody binding A quantitative cell-free binding assay with two alternate formats has been developed for detecting either TIE-2 receptorbody binding or ligand binding and competition.
  • TIE-2 ligands purified or partially purified; either TL1 or TL2
  • Receptorbody at varying concentrations is then added, which binds to the immobilized ligand in a dose-dependent manner.
  • excess receptorbody is washed away, then the amount bound to the plate is reported using a specific anti-human Fc antibody which is alkaline phosphatase tagged.
  • Excess reporter antibody is washed away, then the AP reaction is developed using a colored substrate.
  • FIG. 19 shows a typical TIE-2-IgG binding curve. This assay has been used to evaluate the integrity of TIE-2-IgG after injection into rats and mice.
  • the assay can also be used in this format as a ligand competition assay, in which purified or partially-purified TIE ligands compete with immobilized ligand for receptorbody. In the ligand binding and competition version of the binding assay, TIE-2 ectodomain is coated onto the ELISA plate.
  • the Fc-tagged fibrinogen-like domain fragments of the TIE ligands (TL1-fFc and TL2-fFc) then bind to the ectodomain, and can be detected using the same anti-human Fc antibody as described above.
  • FIG. 20 shows an example of TL1-fFc binding to TIE-2 ectodomain.
  • This version of the assay can also be used to quantitate levels of TL1-fFc in serum or other samples. If untagged ligand (again, either purified or unpurified) is added at the same time as the TL1-fFc, then a competition is set up between tagged ligand fragment and full-length ligand. The full-length ligand can displace the Fc-tagged fragment, and a competition curve is generated.
  • EA.hy926 is a cell hybrid line that was established by fusion of HUVEC with the human lung carcinoma-derived line, A549 [Edgell, et al.
  • EA.hy926 cells have been found to express significant levels of TIE-2 receptor protein with low basal phosphotyrosine levels.
  • the density at which EA.hy926 cells are passaged prior to their use for receptor assays, as well as their degree of confluency at the time of assay, can affect TIE-2 receptor abundance and relative inducibility in response to treatment with ligand.
  • the EA.hy926 cell line can be used as a dependable system for assay of TIE-2 ligand activities.
  • EA.hy926 cells are seeded at 1.5 ⁇ 10 6 cells in T-75 flasks (Falconware) and re-fed every other day with high-glucose Dulbecco's MEM, 10% fetal bovine serum, L-glutamine, penicillin-streptomycin, and 1 ⁇ hypoxanthine-aminopterin-thymidine (HAT, Gibco/BRL). After three to four days of growth, the cells are passaged once again at 1.5 ⁇ 10 6 cells per T-75 flask and cultured an additional three to four days.
  • HAT hypoxanthine-aminopterin-thymidine
  • phosphorylation assays For phosphorylation assays, cells prepared as described above were serum-starved by replacement of the culture medium with high-glucose DMEM and incubation for 2-3 hours at 37° C. This medium was aspirated from the flask and samples of conditioned media or purified ligand were added to the flask in a total volume of 1.5 ml followed by incubation at 37° C. for 5 minutes. Flasks were removed from the incubator and placed on a bed of ice.
  • the medium was removed and replaced with 1.25 ml Lysis Buffer containing 1% nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS in 20 mM Tris, pH 7.6, 150 mM NaCl, 50 mM NaF, 1 mM sodium orthovanadate, 5 mM benzamidine, and 1 mM EDTA containing the protease inhibitors PMSF, aprotinin, and leupeptin. After 10 minutes on ice to allow membrane solubilization, plates were scraped and cell lysates were clarified by microcentrifugation at top speed for 10 minutes at 4° C.
  • TIE-2 receptor was immunoprecipitated from the clarified supernatant by incubation in the cold with an anti-TIE-2 polyclonal antiserum and Protein G-conjugated Sepharose beads. The beads were washed three times with cold cell lysis buffer and boiled 5 minutes in Laemmli sample buffer, which was then loaded on 7.5% SDS-polyacrylamide gels. Resolved proteins were electrotransferred to PVDF (Lamblia-P) membrane and then subjected to Western blot analysis using anti-phosphotyrosine antibody and the ECL reagent. Subsequent comparison of total TIE-2 protein levels on the same blots was done by stripping the anti-phosphotyrosine antibody and reincubating with a polyclonal antiserum specific to the ectodomain of TIE-2.
  • TIE ligand-3 (TL3) was cloned from a mouse BAC genomic library (Research Genetics) by hybridizing library duplicates, with either mouse TL1 or mouse TL2 probes corresponding to the entire coding sequence of those genes. Each copy of the library was hybridized using phosphate buffer at 55° C. overnight. After hybridization, the filters were washed using 2 ⁇ SSC, 0.1% SDS at 60° C., followed by exposure of X ray film to the filters. Strong hybridization signals were identified corresponding to mouse TL1 and mouse TL2. In addition, signals were identified which weakly hybridized to both mouse TL1 and mouse TL2.
  • DNA corresponding to these clones was purified, then digested with restriction enzymes, and two fragments which hybridized to the original probes were subcloned into a bacterial plasmid and sequenced.
  • the sequence of the fragments contained two exons with homology to both mouse TL1 and mouse TL2.
  • Primers specific for these sequences were used as PCR primers to identify tissues containing transcripts corresponding to TL3.
  • a PCR band corresponding to TL3 was identified in a mouse uterus cDNA library in lambda gt-11. (Clontech Laboratories, Inc., Palo Alto, Calif.).
  • Plaques were plated at a density of 1.25 ⁇ 10 6 /20 ⁇ 20 cm plate and replica filters taken following standard procedures (Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., page 8.46, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). Duplicate filters were screened at “normal” stringency (2 ⁇ SSC, 65° C.) with a 200 bp PCR radioactive probe made to the mouse TL3 sequence. Hybridization was at 65° C. in a solution containing 0.5 mg/ml salmon sperm DNA. Filters were washed in 2 ⁇ SSC at 65° C. and exposed for 6 hours to X-ray film. Two positive clones that hybridized in duplicate were picked.
  • PCR reactions were performed using expression libraries derived from the mouse cell lines C2C12ras and MG87.
  • the specific primer US2 was used in conjunction with vector-specific oligos to allow amplification in either orientation.
  • PCR was in a total volume of 100 ml using 35 cycles of 94° C., 1 min; 42° C. or 48° C. for 1 min; 72° C., 1 min.
  • the secondary PCR reaction included the second specific primer, US1, which is contained within the primary PCR product, in conjunction with the same vector oligos. The secondary reactions were for 30 cycles, using the same temperatures and times as previous. PCR products were gel isolated and submitted for sequence analysis.
  • TL3 On the basis of sequences obtained from a total of four independent PCR reactions using two different cDNA libraries, the 5′ end of the TL3 sequence was deduced. Northern analysis revealed moderate to low levels of mouse TL3 transcript in mouse placenta. The expression of mouse TL3 consisted of a transcript of approximately 3 kb. The full length TL3 coding sequence is set forth in FIGS. 21A-21C (SEQ. ID. NO. 9 and SEQ. ID. NO. 10).
  • the mouse TL3 sequence may then be used to obtain a human clone containing the coding sequence of human TL3 by hybridizing either a human genomic or cDNA library with a probe corresponding to mouse TL3 as has been described previously, for example, in Example 8 supra.
  • TIE ligand-4 was cloned from a mouse BAC genomic library (BAC HUMAN (II), Genome Systems Inc.) by hybridizing library duplicates, with either a human TL1 radioactive probe corresponding to the entire fibrinogen coding sequence of TL1 (nucleotides 1153 to 1806 of FIGS. 4A-4D (SEQ. ID. NO. 1 and SEQ. ID. NO. 2)) or a mouse TL3 radioactive probe corresponding to a segment of 186 nucleotides from the fibrinogen region of mouse TL3 (nucleotides 1307 to 1492 of FIGS. 21A-21C (SEQ. ID. NO. 9 and SEQ. ID. NO. 10)).
  • Each probe was labeled by PCR using exact oligonucleotides and standard PCR conditions, except that dCTP was replaced by P 32 dCTP.
  • the PCR mixture was then passed through a gel filtration column to separate the probe from free p 32 dCTP.
  • Each copy of the library was hybridized using phosphate buffer, and radiactive probe at 55° C. overnight using standard hybridization conditions. After hybridization, the filters were washed using 2 ⁇ SSC, 0.1% SDS at 55° C., followed by exposure of X ray film. Strong hybridization signals were observed corresponding to human TL1. In addition, signals were identified which weakly hybridized to both human TL1 and mouse TL3.
  • DNA corresponding to these clones was purified using standard procedures, then digested with restriction enzymes, and one fragment which hybridized to the original probes was subcloned into a bacterial plasmid and sequenced.
  • the sequence of the fragments contained one exon with homology to both human TL1 and mouse TL3 and other members of the TIE ligand family. Primers specific for these sequences may be used as PCR primers to identify tissues containing transcripts corresponding to TL4.
  • the complete sequence of human TL4 may be obtained by sequencing the full BAC clone contained in the deposited bacterial cells. Exons may be identified by homology to known members of the TIE-ligand family such as TL1, TL2 and TL3. The full coding sequence of TL4 may then be determined by splicing together the exons from the TL4 genomic clone which, in turn, may be used to produce the TL4 protein. Alternatively, the exons may be used as probes to obtain a full length cDNA clone, which may then be used to produce the TL4 protein.
  • Exons may also be identified from the BAC clone sequence by homology to protein domains such as fibrinogen domains, coiled coil domains, or protein signals such as signal peptide sequences. Missing exons from the BAC clone may be obtained by identification of contiguous BAC clones, for example, by using the ends of the deposited BAC clone as probes to screen a human genomic library such as the one used herein, by using the exon sequence contained in the BAC clone to screen a cDNA library, or by performing either 5′ or 3′ RACE procedure using oligonucleotide primers based on the TL4 exon sequences.
  • the novel TIE ligand-4 sequence may be used in a rational search for additional members of the TIE ligand family using an approach that takes advantage of the existence of conserved segments of strong homology between the known family members. For example, an alignment of the amino acid sequences of the TIE ligands shows several regions of conserved sequence (see boxed regions of FIGS. 22A-22B (SEQ ID. NO. 11, SEQ. ID. NO. 12, SEQ. ID. NO. 13, SEQ, ID. NO. 14, SEQ. ID. NO. 15, and SEQ. ID. NO. 16)). Degenerate oligonucleotides essentially based on these boxes in combination with either previously known or novel TIE ligand homology segments may be used to identify new TIE ligands.
  • TL1, TL2 and TL3 may be used in designing degenerate oligonucleotide primers with which to prime PCR reactions using cDNAs.
  • cDNA templates may be generated by reverse transcription of tissue RNAs using oligo d(T) or other appropriate primers. Aliquots of the PCR reactions may then be subjected to electrophoresis on an agarose gel. Resulting amplified DNA fragments may be cloned by insertion into plasmids, sequenced and the DNA sequences compared with those of all known TIE ligands.
  • Size-selected amplified DNA fragments from these PCR reactions may be cloned into plasmids, introduced into E. coli by electroporation, and transformants plated on selective agar. Bacterial colonies from PCR transformation may be analyzed by sequencing of plasmid DNAs that are purified by standard plasmid procedures.
  • Cloned fragments containing a segment of a novel TIE ligand may be used as hybridization probes to obtain full length cDNA clones from a cDNA library.
  • the human TL4 genomic sequence may be used to obtain a human cDNA clone containing the complete coding sequence of human TL4 by hybridizing a human cDNA library with a probe corresponding to human TL4 as has been described previously.
  • Both 5′ and 3′ coding sequence from the genomic human TL-4 clone encoding human TIE ligand-4 was obtained by restriction enzyme digestion, Southern blotting and hybridization of the hTL-4 clone to coding sequences from mouse TL3, followed by subcloning and sequencing the hybridizing fragments. Coding sequences corresponding to the N-terminal and C-terminal amino acids of hTL4 were used to design PCR primers (shown below), which in turn were used for PCR amplification of TL4 from human ovary cDNA.
  • a PCR band was identified as corresponding to human TL4 by DNA sequencing using the ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, Calif.). The PCR band was then subcloned into vector pCR-script and several plasmid clones were analyzed by sequencing. The complete human TL4 coding sequence was then compiled and is shown in FIGS. 23A-23C (SEQ ID. NO. 17and SEQ. ID. NO. 18).
  • the nucleotide at position 569 is changed from A to G, resulting in an amino acid change from Q to R.
  • PCR primers used as described above were designed as follows:
  • TIE-2 ligand-1 and TIE-2 ligand-2 were undertaken to gain insight into a number of their observed properties.
  • TL1 and TL2 share similar structural homology, they exhibit different physical and biological properties.
  • the most prominent feature that distinguishes the two ligands is that although they both bind to the TIE-2 receptor, TL1 is an agonist while TL2 is an antagonist. Under non-reducing electrophoretic conditions both proteins exhibit covalent, multimeric structures.
  • TL1 is produced as a mixture of disulfide cross-linked multimers, primarily trimers and higher order species, without any dimeric species. But TL2 is produced almost exclusively as a dimeric species.
  • TL1 is expressed poorly and is difficult to produce in large quantities.
  • production and purification conditions also appear to predispose TL1 to inactivation by proteolytic cleavage at a site near the amino terminus.
  • Cysteine substitution Investigations into what factors might be contributing to the different physical and biological properties of the two molecules revealed the presence in TL1 of a cysteine residue (CYS 265 in FIGS. 4A-4D (SEQ. ID. NO. 1 and SEQ. ID. NO. 2); CYS 245 in FIG. 17 (SEQ. ID. NO. 7 and SEQ. ID. NO. 8)) preceding the fibrinogen-like domain in TL1 but absent in TL2—i.e., there was no corresponding cysteine residue in TL2.
  • the CYS265 residue in TL1 is encoded by TGC and is located at about nucleotides 1102-1104 (see FIGS. 4A-4D (SEQ. ID. NO.
  • cysteine residues are generally involved in disulfide bond formation, the presence of which can contribute to both the tertiary structure and biological properties of a molecule, it was thought that perhaps the presence of the CYS265 residue in TL1 might be at least partially responsible for the different properties of the two molecules.
  • an expression plasmid was constructed which contained a mutation in TL1 in which the CYS (residue 265 in FIGS. 4A-4D (SEQ. ID. NO. 1 and SEQ. ID. NO. 2); residue 245 in FIG. 17 (SEQ. ID. NO. 7 and SEQ. ID. NO. 8)) was replaced with an amino acid (serine) which does not form disulfide bonds.
  • a second expression plasmid was constructed which mutated the approximately corresponding position in TL2 (Met247 in FIG. 17 (SEQ. ID. NO. 7 and SEQ. ID. NO. 8)) so that this residue was now a cysteine.
  • Both non-mutated and mutated expression plasmids of TL1 and TL2 were transiently transfected into COS7 cells, cell supernatants containing the recombinant proteins were harvested, and samples were subjected to both reducing and non-reducing SDS/PAGE electrophoresis and subsequent Western blotting.
  • FIG. 18 shows the Western blots under non-reducing conditions of both non-mutated and mutated TL1 and TL2 proteins, revealing that the TL1/CYS ⁇ mutant runs as a dimer much like TL2 and that the TL2/CYS+ mutant is able to form a trimer, as well as higher-order multimers, more like TL1.
  • the two mutant proteins were tested for their ability to induce phosphorylation in TIE-2 expressing cells, the TL1/CYS ⁇ mutant was able to activate the TIE-2 receptor, whereas the TL2/CYS + mutant was not.
  • the supernatant containing the recombinant protein was harvested.
  • the TL1/F-domain mutant was tested for its ability to bind the TIE-2 receptor. The results showed that, as a monomer, the TL1/F-domain mutant was not able to bind TIE-2 at a detectable level.
  • TL1/F-domain monomer was myc-tagged and subsequently clustered with an antibody directed against the myc tag, it exhibited detectable binding to TIE-2.
  • the antibody-clustered TL1/F-domain mutant was not able to induce phosphorylatioh in a TIE-2 expressing cell line.
  • TL1 level of production of TL1 in COS7 cells was approximately tenfold lower than production of TL2. Therefore, chimeras of TL1 and TL2 were constructed in an attempt to explain this difference and also to further characterize the agonist activity of TL1 as compared to the antagonist activity of TL2.
  • chimeras were constructed in which either the N-terminal domain or the fibrinogen domain was exchanged between TL1 and TL2 and were designated using the terminology described previously such that, for example, 1N1C2F refers to a chimera having the N-terminal and coiled-coil domains of TL1, together with the fibrinogen-like domain from TL2.
  • the four chimeras were constructed as follows:
  • FIGS. 24A-24C The nucleotide and amino acid sequences of chimeras 1-4 are shown in FIGS. 24A-24C, FIGS. 25A-25C, FIGS. 26A-26C, and FIGS. 27A-27C (SEQ. ID. NOS. 19-26) respectively.
  • Each chimera was inserted into a separate expression vector pJFE14.
  • the chimeras were then transfected into COS7 cells, along with the empty pJFE14 vector, native TL1, and native TL2 as controls, and the culture supernatants were collected.
  • a 1:5 dilution and a 1:50 dilution of the COS7 supernatants were dot-blotted onto nitrocellulose.
  • Three ligands that contained the TL1 N-domain i.e. native TL1, 1N2C2F and 1N1C2F
  • Three ligands containing the TL2 N-domain, (i.e. native TL2, 2N1C1F and 2N2C1F) were probed with a rabbit antibody specific for the N-terminus of TL2.
  • EAhy926 cells were challenged with the four chimeras, as well as TL1 as a positive control for phosphorylation and TL2 or an empty pJFE14-transfected COS7 cell supernatant as negative controls for phosphorylation. The cells were lysed, and the TIE-2 receptor was immunoprecipitated out of the cell lysate and run on an SDS-PAGE. The samples were Western blotted and probed with an anti-phosphotyrosine antibody to detect any receptors that had been phosphorylated.
  • TL1 fibrinogen-like domain 2N1C1F and 2N2C1F
  • the N-terminal region of TL1 is essential for activation, it can be replaced by the N-terminal region of TL2, i.e., the information that determines whether the ligand is an agonist or an antagonist is actually contained in the fibrinogen-like domain.
  • the F-domain in addition to binding the TIE-2 receptor, is responsible for the phosphorylation activity of TL1.
  • an otherwise inactive molecule was altered by replacing its F-domain with the TL1 F-domain, the altered TL2 acted as an agonist.
  • the 2N1C1F construct was somewhat more potent, however.
  • the signal caused by chimera 2N1C1F appeared slightly stronger than that of chimera 2N2C1F, leading to speculation that the C-domain of TL1, though not crucial for phosphorylation, might enhance the potency of TL1.
  • the samples used for the phosphorylation assay were not normalized in terms of the concentration of ligand, it was possible that a stronger phosphorylation signal only indicated the presence of more ligand.
  • the phosphorylation assay was therefore repeated with varying amounts of ligand to determine whether the active chimeras displayed different potencies.
  • the concentration of ligand in the COS7 supernatants of ligand transfections was determined through BIAcore biosenser technology according to methods previously described (Stitt, T. N., et al. (1995) Cell 80: 661-670).
  • BIAcore measured the binding activity of a supernatant to the TIE-2 receptor in arbitrary units called resonance units (RU). Fairly good correlation between RU's and ligand concentration has been generally observed, with 400 RU of activity corresponding to about 1 ⁇ g of protein per mL of supernatant.
  • Samples were diluted to concentrations of 100 RU, 20 RU, and 5 RU each and the phosphorylation assay was repeated. The results demonstrated that chimera 2N2C1 F was clearly more potent than either the native TL1 or chimera 1N1C2F at the same concentrations.
  • this molecule was further altered to eliminate the potentially protease sensitive site encoded by nucleotides 199-201 as shown in FIGS. 27A-27C (SEQ. ID. NO. 25 and SEQ. ID. NO. 26), to give a molecule (denoted 2N1C1F (R51->S,C246->S)) which was expected to be activating, well expressed, dimeric, and protease resistant.
  • Table 1 summarizes the modified TIE-2 ligand constructs that were made and characterizes each of them in terms of ability to bind the TIE-2 receptor, ability to activate the TIE-2 receptor, the type of structure formed (monomer, dimer, etc.) and their relative production levels.
  • Unmodified TL1 (plain) and TL2 (striped) are shown with the three domains as boxes. Thus striped boxes indicate domains from TL2.
  • the cysteine located at position 245 of the mature TL1 protein is indicated by a “C.”
  • An “X” through the “C” indicates that that cysteine residue was substituted for by another amino acid as in, for example, the TL1 CYS ⁇ mutant.
  • an “X”, through the “R” in the last construct indicates the substitution for an Arg residue at position 49 of the mature TL1 protein.
  • the “C” is present in one modified TL2 construct showing the TL2 CYS + mutant. Constructs having Fc tails or flag tagging are also indicated. Based upon the teachings herein, one of skill in the art can readily see that further constructs may be made in order to create additional modified and chimeric TIE-2 ligands which have altered properties. For example, one may create a construct comprised of the N-terminal domain of TL2 and the F-domain of TL1 fused with the Fc section of human antibody IgG1. This construct would be expected to bind and activate the TIE-2 receptor. Similarly, other constructs may be created using the teachings herein and are therefore considered to be within the scope of this invention.
  • Swapping constructs were inserted into a pJFE14 vector in which the Xbal site was changed to an Ascl site. This vector was then digested with Ascl and NotI yielding an AscI-NotI backbone. DNA fragments for the chimeras were generated by PCR using appropriate oligonucleotides.
  • the FLAG-1C1F and FLAG-2C2F inserts were subcloned into a pMT21 vector backbone that had been digested with EcoRI and Notl.
  • the “CF” truncations were obtained through PCR, and the FLAG tag and a preceding trypsin signalling sequence were constructed by annealing synthetic oligonucleotides.
  • 6-well dishes of COS7 cells were transfected transiently with the TIE-2 receptor.
  • the COS7 supernatant from various ligand tansfections was incubated on the cells for 30 minutes, followed by two washes with Phosphate Buffered Saline (PBS) without magnesium or calcium.
  • PBS Phosphate Buffered Saline
  • the cells were fixed in ⁇ 20° C. methanol for 3 minutes, washed once with PBS, and incubated with anti-FLAG M2 antibody (IBI;1:3000 dilution) in PBS/10% Bovine Calf Serum (BCS) for 30 minutes.
  • the cells were washed once with PBS and incubated with goat anti-mouse IgG Alkaline Phosphatase (AP) conjugated antibody (Promega;1:1000) in PBS/10% BCS.
  • the cells were washed twice with PBS and incubated with the phosphate substrate, BCIP/NBT, with 1 mM levamisole.
  • a plasmid clone encoding a TIE-2 ligand was deposited with the ATCC on Oct. 7, 1994 and designated as “pJFE14 encoding TIE-2 ligand” under ATCC Accession No. 75910.
  • Recombinant Autographa californica baculovirus encoding TIE-2 receptorbody was deposited with the ATCC on Oct. 7, 1994 and designated as “vTIE-2 receptorbody” under ATCC Accession No. VR2484.
  • a lambda phage vector containing human tie-2 ligand DNA was deposited with the ATCC on Oct.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
US08/740,223 1996-08-02 1996-10-25 Expressed ligand-vascular intercellular signalling molecule Expired - Lifetime US6265564B1 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
US08/740,223 US6265564B1 (en) 1996-08-02 1996-10-25 Expressed ligand-vascular intercellular signalling molecule
PT97937086T PT915974E (pt) 1996-08-02 1997-08-01 Ligandos de receptores de tie-2 modificados
IL128311A IL128311A (en) 1996-08-02 1997-08-01 Changed receptors - Tai-2 - receptor
HU0400256A HU227995B1 (en) 1996-08-02 1997-08-01 Modified tie-2-receptor ligands
KR10-1999-7000894A KR100481560B1 (ko) 1996-08-02 1997-08-01 변형된 ｔｉｅ-2-수용체 리간드
DK97937086T DK0915974T3 (da) 1996-08-02 1997-08-01 Modificerede tie-2 receptor-ligander
PCT/US1997/013557 WO1998005779A1 (en) 1996-08-02 1997-08-01 Modified tie-2-receptor ligands
CA002595037A CA2595037A1 (en) 1996-08-02 1997-08-01 Modified tie-2 receptor ligands
JP50808798A JP3977434B2 (ja) 1996-08-02 1997-08-01 改変ｔｉｅ―２レセプターリガンド
EP97937086A EP0915974B1 (en) 1996-08-02 1997-08-01 Modified tie-2-receptor ligands
ES97937086T ES2216163T3 (es) 1996-08-02 1997-08-01 Ligandos modificados del receptor tie-2.
CNB971985316A CN1171997C (zh) 1996-08-02 1997-08-01 修饰的tie-2受体配体
RU99105129/13A RU2233880C2 (ru) 1996-08-02 1997-08-01 Выделенная молекула нуклеиновой кислоты, кодирующая химерный tie-2-лиганд (варианты), химерный или модифицированный tie-2-лиганд и способ его получения, вектор, способ получения системы вектор-хозяин, конъюгат, фармацевтическая композиция
PL97331405A PL189639B1 (pl) 1996-08-02 1997-08-01 Wyodrębniona cząsteczka kwasu nukleinowego, chimeryczny ligand TIE-2, wektor, układ gospodarz-wektor, sposób wytwarzania liganda, przeciwciało, koniugat, kompozycja farmaceutyczna i chimeryczny ligand
NZ505684A NZ505684A (en) 1996-08-02 1997-08-01 Chimeric tie-2-receptor ligand 1 which binds and activates the tie-2 receptor
CA2595038A CA2595038C (en) 1996-08-02 1997-08-01 Modified tie-2 receptor ligands
NZ333994A NZ333994A (en) 1996-08-02 1997-08-01 Chimeric TIE-2 (tyrosine kinase with Ig and EGF homology) ligands
CZ1999310A CZ295371B6 (cs) 1996-08-02 1997-08-01 Izolovaná molekula nukleové kyseliny kódující chimerní TIE-2 ligand, chimerní TIE-2 ligand kódující molekulu nukleové kyseliny, vektor zahrnující molekulu nukleové kyseliny, způsob produkce ligandu, konjugát obsahující ligand a farmaceutický prostředek, obsahující ligand
CA002262409A CA2262409C (en) 1996-08-02 1997-08-01 Modified tie-2-receptor ligands
AT97937086T ATE262037T1 (de) 1996-08-02 1997-08-01 Modifizierte liganden für den tie-2-rezeptor
DE69728149T DE69728149T2 (de) 1996-08-02 1997-08-01 Modifizierte liganden für den tie-2-rezeptor
AU39687/97A AU724032C (en) 1996-08-02 1997-08-01 Modified tie-2-receptor ligands
NO990470A NO990470L (no) 1996-08-02 1999-02-01 Modifiserte TIE-2-reseptorligander
HK99102434A HK1017379A1 (en) 1996-08-02 1999-06-02 Modified tie-2-receptor ligands
US09/709,188 US6441137B1 (en) 1996-08-02 2000-11-09 Expressed ligand-vascular intercellular signalling molecule
NZ514437A NZ514437A (en) 1996-08-02 2001-09-25 A chimeric TIE-2-receptor ligand that binds to but does not activate TIE-2
US10/225,060 US6825008B2 (en) 1996-08-02 2002-08-21 Expressed ligand—vascular intercellular signalling molecule
US10/928,911 US20050106099A1 (en) 1996-08-02 2004-08-27 Expressed ligand-vascular intercellular signaling molecule
US11/073,120 US7045302B2 (en) 1996-08-02 2005-03-04 Expressed ligand-vascular intercellular signaling molecule

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2299996P 1996-08-02 1996-08-02
US08/740,223 US6265564B1 (en) 1996-08-02 1996-10-25 Expressed ligand-vascular intercellular signalling molecule

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/709,188 Division US6441137B1 (en) 1996-08-02 2000-11-09 Expressed ligand-vascular intercellular signalling molecule
US09/709,188 Continuation US6441137B1 (en) 1996-08-02 2000-11-09 Expressed ligand-vascular intercellular signalling molecule

Publications (1)

Publication Number Publication Date
US6265564B1 true US6265564B1 (en) 2001-07-24

Family

ID=26696604

Family Applications (5)

Application Number Title Priority Date Filing Date
US08/740,223 Expired - Lifetime US6265564B1 (en) 1996-08-02 1996-10-25 Expressed ligand-vascular intercellular signalling molecule
US09/709,188 Expired - Lifetime US6441137B1 (en) 1996-08-02 2000-11-09 Expressed ligand-vascular intercellular signalling molecule
US10/225,060 Expired - Lifetime US6825008B2 (en) 1996-08-02 2002-08-21 Expressed ligand—vascular intercellular signalling molecule
US10/928,911 Abandoned US20050106099A1 (en) 1996-08-02 2004-08-27 Expressed ligand-vascular intercellular signaling molecule
US11/073,120 Expired - Fee Related US7045302B2 (en) 1996-08-02 2005-03-04 Expressed ligand-vascular intercellular signaling molecule

Family Applications After (4)

Application Number Title Priority Date Filing Date
US09/709,188 Expired - Lifetime US6441137B1 (en) 1996-08-02 2000-11-09 Expressed ligand-vascular intercellular signalling molecule
US10/225,060 Expired - Lifetime US6825008B2 (en) 1996-08-02 2002-08-21 Expressed ligand—vascular intercellular signalling molecule
US10/928,911 Abandoned US20050106099A1 (en) 1996-08-02 2004-08-27 Expressed ligand-vascular intercellular signaling molecule
US11/073,120 Expired - Fee Related US7045302B2 (en) 1996-08-02 2005-03-04 Expressed ligand-vascular intercellular signaling molecule

Country Status (21)

Country Link
US (5) US6265564B1 (no)
EP (1) EP0915974B1 (no)
JP (1) JP3977434B2 (no)
KR (1) KR100481560B1 (no)
CN (1) CN1171997C (no)
AT (1) ATE262037T1 (no)
AU (1) AU724032C (no)
CA (1) CA2262409C (no)
CZ (1) CZ295371B6 (no)
DE (1) DE69728149T2 (no)
DK (1) DK0915974T3 (no)
ES (1) ES2216163T3 (no)
HK (1) HK1017379A1 (no)
HU (1) HU227995B1 (no)
IL (1) IL128311A (no)
NO (1) NO990470L (no)
NZ (2) NZ505684A (no)
PL (1) PL189639B1 (no)
PT (1) PT915974E (no)
RU (1) RU2233880C2 (no)
WO (1) WO1998005779A1 (no)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441137B1 (en) 1996-08-02 2002-08-27 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
WO2003048185A2 (en) * 2001-11-30 2003-06-12 Genvec, Inc. Angiopioetin related factors
US7008781B1 (en) * 1998-12-23 2006-03-07 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of ligands
US20110165650A1 (en) * 2004-01-16 2011-07-07 Regeneron Pharmaceuticals, Inc. Fusion Polypeptides Capable of Activating Receptors
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2671891A2 (en) 2008-06-27 2013-12-11 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US20140113858A1 (en) * 2012-10-18 2014-04-24 Samsung Electronics Co., Ltd. Peptide for inhibition of binding between angiopoietin-2 and integrin and use thereof
WO2017079556A1 (en) 2015-11-06 2017-05-11 Regeneron Pharmaceuticals, Inc. Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
CA2397833A1 (en) * 2000-01-20 2001-07-26 Hadasit Medical Research Services & Development Company Ltd. Novel haptotactic peptides
MXPA03001535A (es) 2000-08-21 2004-12-13 Pacific Corp Derivados de tiourea novedosos y las composiciones farmaceuticas que contienen los mismos.
US6753321B2 (en) 2000-09-15 2004-06-22 Genvec, Inc. Method of modulating neovascularization
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7052695B2 (en) 2001-10-25 2006-05-30 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of treating hypertension
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
WO2004076650A2 (en) * 2003-02-27 2004-09-10 The Trustees Of The University Of Pennsylvania Angiopoietin and fragments, mutants, and analogs thereof and uses of the same
US8232247B2 (en) * 2003-05-29 2012-07-31 The Trustees Of The University Of Pennsylvania Methods of treating cancer, arthritis and/or diabetes with angiopoietins
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
WO2005019267A2 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
CN1323723C (zh) * 2003-12-26 2007-07-04 上海新世界基因技术开发有限公司 Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统
CN105085678B (zh) 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2758120C (en) * 2009-04-13 2014-08-19 Apceth Gmbh & Co. Kg Engineered mesenchymal stem cells and method of using same to treat tumors
RU2538701C1 (ru) * 2013-07-11 2015-01-10 Федеральное государственное бюджетное учреждение науки "Тюменский научный центр Сибирского отделения РАН" (ТюмНЦ СО РАН) Способ извлечения куриного эмбриона из яйца для дальнейшего получения клеточных трансплантатов из фетальных тканей
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070192A (en) * 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
WO1996011269A2 (en) * 1994-10-07 1996-04-18 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031598A1 (en) * 1995-04-06 1996-10-10 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070192A (en) * 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
WO1996011269A2 (en) * 1994-10-07 1996-04-18 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Rudinger, J. in Peptide Hormones, Parson, J. A. (Ed.), University Park Press, Baltimore, MD, pp. 1-7, 1976.*
Zhou et al. PNAS 95(5):2492-7, 1998. *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441137B1 (en) 1996-08-02 2002-08-27 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US20030092891A1 (en) * 1996-08-02 2003-05-15 Samuel Davis Expressed ligand - vascular intercellular signalling molecule
US6825008B2 (en) * 1996-08-02 2004-11-30 Regeneron Pharmaceuticals, Inc. Expressed ligand—vascular intercellular signalling molecule
US7045302B2 (en) 1996-08-02 2006-05-16 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signaling molecule
US7008781B1 (en) * 1998-12-23 2006-03-07 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of ligands
WO2003048185A2 (en) * 2001-11-30 2003-06-12 Genvec, Inc. Angiopioetin related factors
WO2003048185A3 (en) * 2001-11-30 2004-06-24 Genvec Inc Angiopioetin related factors
US8597898B2 (en) 2004-01-16 2013-12-03 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US8470324B2 (en) 2004-01-16 2013-06-25 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US20110165650A1 (en) * 2004-01-16 2011-07-07 Regeneron Pharmaceuticals, Inc. Fusion Polypeptides Capable of Activating Receptors
US8865430B2 (en) 2004-01-16 2014-10-21 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US8927233B2 (en) 2004-01-16 2015-01-06 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US9840549B2 (en) 2004-01-16 2017-12-12 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP2671891A2 (en) 2008-06-27 2013-12-11 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US20140113858A1 (en) * 2012-10-18 2014-04-24 Samsung Electronics Co., Ltd. Peptide for inhibition of binding between angiopoietin-2 and integrin and use thereof
KR20140050207A (ko) * 2012-10-18 2014-04-29 삼성전자주식회사 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도
US9193768B2 (en) * 2012-10-18 2015-11-24 Samsung Electronics Co., Ltd. Peptide for inhibition of binding between angiopoietin-2 and integrin and use thereof
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2017079556A1 (en) 2015-11-06 2017-05-11 Regeneron Pharmaceuticals, Inc. Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders

Also Published As

Publication number Publication date
KR100481560B1 (ko) 2005-04-08
EP0915974A1 (en) 1999-05-19
KR20000029778A (ko) 2000-05-25
PL331405A1 (en) 1999-07-19
CN1232501A (zh) 1999-10-20
HUP0400256A2 (hu) 2004-04-28
US20050186665A1 (en) 2005-08-25
JP2000516807A (ja) 2000-12-19
AU3968797A (en) 1998-02-25
CA2262409C (en) 2007-11-20
US20050106099A1 (en) 2005-05-19
US6825008B2 (en) 2004-11-30
JP3977434B2 (ja) 2007-09-19
CZ31099A3 (cs) 2000-03-15
DK0915974T3 (da) 2004-07-12
PT915974E (pt) 2004-05-31
PL189639B1 (pl) 2005-09-30
US7045302B2 (en) 2006-05-16
NO990470L (no) 1999-04-06
US20030092891A1 (en) 2003-05-15
CZ295371B6 (cs) 2005-07-13
WO1998005779A1 (en) 1998-02-12
HU227995B1 (en) 2012-08-28
DE69728149D1 (de) 2004-04-22
IL128311A0 (en) 2000-01-31
NZ333994A (en) 2000-09-29
HUP0400256A3 (en) 2006-01-30
DE69728149T2 (de) 2004-10-28
US6441137B1 (en) 2002-08-27
ATE262037T1 (de) 2004-04-15
CN1171997C (zh) 2004-10-20
AU724032C (en) 2001-08-16
AU724032B2 (en) 2000-09-07
EP0915974B1 (en) 2004-03-17
RU2233880C2 (ru) 2004-08-10
CA2262409A1 (en) 1998-02-12
HK1017379A1 (en) 1999-11-19
IL128311A (en) 2007-08-19
ES2216163T3 (es) 2004-10-16
NZ505684A (en) 2001-12-21
NO990470D0 (no) 1999-02-01

Similar Documents

Publication Publication Date Title
US6265564B1 (en) Expressed ligand-vascular intercellular signalling molecule
US6627415B1 (en) TIE-2 ligands, methods of making and uses thereof
US20030040463A1 (en) TIE-2 ligands, methods of making and uses thereof
US6881395B2 (en) TIE-2 ligand-4
US5851797A (en) Tie ligand-3, methods of making and uses thereof
US20030166858A1 (en) TIE-2 ligands, methods of making and uses thereof
US7063965B2 (en) Nucleic acid encoding TIE-2 ligand
US6846914B2 (en) Tie-2 ligand-3
CA2595038C (en) Modified tie-2 receptor ligands
AU755337B2 (en) New uses of tie-2 ligands
AU741134B2 (en) Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
AU749312B2 (en) Novel modified tie-2 receptor ligands

Legal Events

Date Code Title Description
AS Assignment

Owner name: REGENERON PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAVIS, SAMUEL;YANCOPOULOS, GEORGE D.;REEL/FRAME:008813/0826

Effective date: 19970801

AS Assignment

Owner name: REGENERON PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAVIS, SAMUEL;YANCOPOULOS, GEORGE D.;REEL/FRAME:008697/0917

Effective date: 19970911

AS Assignment

Owner name: REGENTS PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAVIS, SAMUEL;YANCOPOULOS, GEORGE D.;REEL/FRAME:009908/0948

Effective date: 19970801

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12